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Chapter 1: General Introduction 
 
1.1. Normal foetal presentation at term 
1.1.1. Cephalic position: definition and prevalence 
About 95% of all foetuses are in cephalic presentation at term. A cephalic 
presentation is the birth situation in which the foetus is lying in a longitudinal 
position with his head in the pelvic channel. The most common form of cephalic 
presentation (i.e., 95% of all cases) is the vertex presentation where the head is 
flexed sharply so that the chin is in contact with the thorax. As a result the 
occiput fontanel is the presenting part, and, hence, this presentation is referred 
to as vertex or occiput presentation. A much less common form of cephalic 
presentation is referred to as face presentation. This type of birth presentation 
is characterized by a pronounced extention of the foetal neck, so that the 
occiput touches the spine, and the face enters first in the birth canal.1  
 
1.1.2. Physiology of cephalic presentation  
Several hypotheses have been postulated to explain cephalic presentation at 
term.  
1) The width of the uterine fundus and the relative narrowness of the pelvic 
segment has led to the notion that foetal kicking enables the foetus to move 
into cephalic position.2,3  
2) Labour itself may also have an effect on presentation at term.4-6 As such one 
may argue that Braxton Hicks contractions in the second half of pregnancy 
contribute to the rotation of the foetus into cephalic position.  
3) It has also been suggested that moving into cephalic position may function as 
a “reward” for the foetus in terms of a less noisy foetal environment. In breech, 
for instance, the greater amount of amniotic fluid surrounding the head may 
facilitate the transmission of sound to the foetal skull, thereby creating 
uncomfortable loudness levels.7  
4) From 24-35 weeks onwards, foetal maturation produces a constant change of 
lie and presentation. This maturation process is in caudiocranial direction and 
mediated by the interplay between inhibitory and stimulatory influences of the 
reticular nuclei and cerebellum. Lower extremity antigravity movements 
including sudden leg extensions, kicking and body rolling are prominent in this 
process. In the cephalic position, the foetus is allowed an uncompromised 
posture in the caudal parts of the body segments along gravity.8 For example: 
paraplegic and tetraplegic pregnant females, who spend their pregnancy in 
horizontal supination or close to it, have a high percentage of non-cephalic 





1.2. Breech presentation 
 
1.2.1. Definition of breech 
In the breech presentation the foetus enters the birth canal with the buttocks 
or feet first as opposed to the normal head first presentation. There are three 
types of breech presentation: (1) frank breech where the foetus’ legs are 
extended up to its head; (2) complete breech where the foetus’ legs are flexed 
back to the bottom; (3) breech where one or both legs are extended below the 
foetus’ bottom.11  
 
1.2.2. Epidemiology 
In The Netherlands, about 6000 live term singleton breech births occur every 
year.12 The incidence of breech presentation decreases with increasing 
gestational age from approximately 16% at 32 weeks to 3-5% of all pregnancies 
at term.4,13  
 
1.2.3. Spontaneous course of breech presentation 
Until 24 weeks gestation there is no tendency towards any preferred foetal 
position in utero. This means that until this point in time breech presentation is 
a physiological presentation and that about half of the babies lie in this 
position.6,14,15 When gestation proceeds, the prevalence of breech position 
gradually decreases. Boos et al.16 found foetal position tends to stabilize from 
the 32nd week onwards. An explanation for this observation could be that the 
uterine space available for the foetus to move decreases between 30 and 37 
weeks (as measured by the AFI/EFW ratio = amniotic fluid index/ estimated 
foetal weight ratio).17 Furthermore, it has also been stated that the amount of 
foetal leg movements decreases during the third trimester. This decrease in leg 
movement may be indicative of progressive neurobehavioral maturation.17 
Some authors state that spontaneous version cannot be expected after the 37th 
week of gestation14, whereas others, in contrast, found an incidence of 
spontaneous version at 37 weeks of 25% (28% multiparae / 8% nulliparae).18 
  
1.2.4. Consequences of breech presentation 
 
1.2.4.1. Impact on foetal development 
Foetal heart rate patterns in breech presenting foetuses show more fluctuations 
in (behavioral) state compared with cephalic presenting foetuses.19 This suggests 
that, although breech foetuses move for similar total lengths of time as their 
cephalic counterparts, there are shorter periods of sustained movement and 
they spend a shorter time in any one behavioural state and that breech foetuses 
are neurologically different from their cephalic counterparts. Foetal eye 
movement patterns in utero are also different in breech presenting versus 




movement responses to vibroacoustic (fewer movements) and airborne sound 
(more movements) stimuli.7 Probably the greater amount of amniotic fluid 
surrounding their head facilitates the transmission of sound to their skull 
resulting in greater experienced sound intensity levels in breech babies versus 
cephalic babies. These differences in sensory experiences may affect the 
development of neural networks during the perinatal period.7 A study on 
lateralized head-position in near term babies showed that the development of a 
lateralized head-position preference was less pronounced in breech foetuses 
than in cephalic foetuses. Furthermore, as cephalic foetuses showed a 
preference for a right-sided head position, breech foetuses did not have a clear 
preference for left or right.21 Since breech foetuses have more freedom of head 
movement than cephalic foetuses, this could lead to a less pronounced 
difference in stimulation between the left and the right otoliths, and thus to a 
weaker manifestation of lateralization. This would converge with Previc’s left-
otolithic dominance theory.21 
Foetuses in breech position show a clear preference for an extended leg 
position, whereas cephalic foetuses show more leg crossing.22 
Finally, less spontaneous wrist flexion has been found in breech presenting 
babies of 36-38 weeks gestational age, and was attributed to their less restricted 
intrauterine environment.21 
 
1.2.4.2. Obstetrical outcome in breech 
Breech foetuses are more susceptible to the burden of stress during labour than  
cephalic foetuses.23 Furthermore, vaginal breech delivery in breech presenting 
babies is frequently accompanied by asphyxia from cord compression or cord 
prolapse. Finally, breech presenting babies are at increased risk for traumatic 
injury associated with the delivery of head and shoulders during the final stage of 
expulsion.24 Breech position in most western countries, therefore, is one of the 
most common reasons to perform elective primary Caesarean Section. 
 
1.2.4.3. Neonatal aspects of breech   
Breech babies tend to be smaller and this difference in weight has been shown 
to disappear at about 14 months of age.25 
Breech babies are known to have a typical side-to-side flattening of the skull, 
known as the “Breech Head”.26,27 This altered head shape is the likely reflection 
of intrauterine environmental factors. Once this constraint is relieved post-
natally, the altered head shape has the potential for complete resolution. 
On examination on the second and fourth day of life, newborns delivered in 
breech presentation have a significantly lower score on all active movement 
measurements. In particular, the popliteal angle in these neonates is significantly 
increased, whereas the extension in their hip joints is decreased.28  
Furthermore, over the course of the first 6 postnatal weeks, significantly less hip 




position.29 These motor problems do not seem to disappear with age as 
indicated by findings showing lower limb, reflex and posture problems in 
breech-delivered infants up until the age of 12-18 months.30  
Finally, breech presentation is known to be a major risk factor for the 
development of hip dysplasia. This increased risk of hip dysplasia is unrelated to 
method of delivery and is higher in frank breech than in complete breech 
positions.31 
Infants delivered in breech compared to cephalic position are at increased risk 
for adverse perinatal outcome, and score lower on neurological tests of 
development.19,32 Impaired neurological outcome was found to be unrelated to 
delivery mode 33, suggesting that the in utero neurological impairment found in 
breech presenting foetuses may indeed be contributory to the foetal 
malpresentation. However, whether atypical foetal position leads to in utero 
neurological impairment (through alterations in proprioceptive feedback 
mechanisms) or whether in utero neurological impairment contributes to 
breech presentation is presently unclear.7 
Finally, because breech presentation is associated with adverse obstetric and 
neonatal outcomes, it is often difficult to determine the causal relationships 
between poor outcome on the one hand and intrinsic foetal condition and/or 
birth mechanics on the other.33  
 
1.2.4.4. Long term aspects of breech 
Breech presentation constitutes a significant risk for cerebral palsy (CP), 
especially  among singletons born by vaginal breech delivery at term.34  
In school-aged children, lower vestibular reactions after thermic and rotational 
balance test were found in children born in breech position compared to 
children born in cephalic position.35 
Substantially more hyperkinesia, learning disability, speech and language 
disorders were found among 8-15 year old children born in breech compared 
to born in cephalic presentation. Especially boys born in breech exhibit 
hyperkinesia.36 
Autism spectrum disorders occur more frequently among children born in 
breech position, even after correcting for other complications such as foetal 
distress.37 Probably there is a shared aetiology and not a causal relationship (as 
complications such as foetal distress were eliminated).  
Finally, adult cognitive outcomes in follow-up studies of infants delivered in 
breech presentation are ambiguous. Some studies show no difference in 
intellectual performance between breech and cephalic born adults.38,39 However, 
in a Danish study, young men delivered in breech presentation had lower 





1.2.5. Etiologic aspects of breech presentation 
Ultrasound observations of foetal movement patterns have shown that the 
foetus turns from breech to cephalic presentation through active whole body 
movements such as kicking.41 Foetal kicking near term enables the foetus to 
move into the cephalic position.2,3,14,42  
In a normal term pregnancy, a foetus with normal motility will likely present in 
the cephalic position. Factors within the foetus affecting its motility will 
therefore enhance the chances of a baby presenting in breech position (foetal 
factors). Likewise, external factors affecting foetal mobility may also increase the 
risk of breech presentation (environmental factors). In spite of this, however, 
only in 15% of breech cases, risk factors can be identified.16,43 
 
1.2.5.1. Foetal factors 
Compromised foetal motor abilities resulting in decreased kicking near term 
may prevent the foetus from moving into the vertex position.3 Foetal 
neuromuscular dysfunction is, thus, an established risk factor for breech 
presentation. Similarly, malformations of the central nervous system and 
chromosome anomalies are associated with breech presentation.44 
Cigarette smoking may decrease foetal muscle tone which, in turn, may affect 
foetal mobility. Maternal smoking, therefore, is clearly associated with breech 
presentation.3,42,45,46 In a similar way are alcohol abuse and anticonvulsant 
therapy related with breech presentation.47 
Reduced foetal mobility has also been observed in diabetic pregnancies48, and, as 
such, maternal diabetes constitutes a risk factor for breech presentation.42  
Spontaneous foetal version is depending on normal neuromotor development. 
Foetal size and body symmetry in pregnancy are associated with infant 
neuromotor development: higher foetal weight was found to be beneficial to 
infant neurodevelopment.49 Therefore, as breech babies tend to be smaller for 
gestational age5,18,42-44,46,50-52 impaired neuromotor development could be the 
underlying cause of breech pregnancy. Furthermore, less vigorous foetal 
movements may also result from low birth weight, thereby reducing the chances 
of spontaneous foetal version.53 
It has earlier been suggested that foetal leg extension is a significant aetiological 
factor in breech presentation because leg extension may prevent the infant from 
kicking himself round.2,54 Interestingly, female sex is another factor associated 
with breech presentation17,52,55,56: female babies tend to be less active and 
smaller in size.17,56 Also the shape of the foetal female pelvis and hips could play 
a role.55  
Both maternal and paternal histories of breech delivery have been found to 
increase the risk of breech delivery in first born offspring.43 Recurrence of 
breech delivery between generations suggests that one or more genetic factors 





1.2.5.2. Environmental factors 
Decreased amniotic fluid is associated with a reduction in space available to the 
foetus and, thus, constitutes a risk factor for breech presentation.3,50 
Umbilical cord length (UCL) has repeatedly been found to be shorter in breech 
than in cephalic presentation.46,58-62 Since UCL is a marker of foetal mobility63-65, 
this finding strengthens the notion that foetal motility plays an important role in 
the pathogenesis of breech presentation. Whether short umbilical cord is a 
cause or a consequence of breech presentation remains to be established. 
In the literature correlations between breech presentation and 
primiparity3,5,18,42,44,52, older maternal age5,42, fundal position of the placenta3 and 
ethnicity42 have been reported. 
Primiparity restricts foetal mobility: i.e., there is a combination of less 
intrauterine space and a tense abdominal muscular wall. The amount of uterine 
malformations due to scars or myomas increases with age. Therefore, older 
maternal age is associated with increased risk for breech presentation.5,42 
Breech presentation in a previous pregnancy significantly reduces the chances of 
spontaneous version to vertex. This is probably due to special characteristics of 
the uterus and/or abdominal cavity. Mechanical factors such as a contracted 
pelvis and uterine abnormalities are rare causes of term breech 
presentation.4,44,50  
In case of obvious placental abnormalities, such as placenta previa, cornual 
placenta, the risk of persisting breech presentation is enhanced. 
The significance of the location of the placenta for foetal presentation is 
debatable. No association between spontaneous cephalic version and placental 
position was found in the study of Westgren18, whereas others found a fundal 
position of the placenta to be a causal factor for breech presentation.3,46,66  
Afro American and Filipino women have a decreased risk of breech presentation 
compared to white Caucasian women.42,67 Breech presentation is most frequent 
in urban (non-rural) areas.5,36 
In certain cases, a combination of factors enhances the risk of breech 
presentation. This is, for instance, the case in frank breech presentation. 
Primiparity and frank breech (extended legs) are closely associated (because the 
increased tone in the abdominal wall in primiparae could predispose to 
extended legs). Therefore, it is difficult to determine if extended legs are a 
primary or a secondary factor in the aetiology of breech presentation.18 
 
1.3. Thyroid and breech presentation 
Much attention has been paid on the consequences of breech presentation and 
on strategies to minimize the negative consequences of breech presentation for 
both mother and child. Much less attention, however, has been focused on why 
some foetuses present in breech.57 A better understanding of the causes of 




Further research into the underlying mechanisms of breech presentation is, 
thus, important.57 
Thyroid hormone is an important factor in the development of the foetal central 
nervous system68, and maternal-foetal transfer of thyroxine accounts for up to 
50% of the foetal serum thyroxine level at term.69 Therefore, one might 
speculate about the possibility that maternal thyroid status affects foetal mobility 
and future psychomotor development. Today, several studies have shown that 
even subtle maternal thyroid problems (e.g., elevated TSH or thyroid stimulating 
hormone levels, lower free thyroid hormone (FT4) levels or elevated  thyroid 
peroxidase antibody (TPO-Ab) titers are associated with impaired psychomotor 
development of the offspring  at the age of 3 weeks70, 10 months71, 1-2 years72, 
18 months73, 23-30 months74, 5 years75, 7-9 years76. Other studies, however, 
deny such an association.77  
Maternal thyroid hormone (high-normal TSH) during late gestation has been 
associated with abnormal cephalic foetal position at birth.78 
A population-based cohort study from Finland recently demonstrated that 
noncephalic presentation at birth was more common among Thyroidglobulin 
antibody (TG-Ab) positive mothers.79 Because Finland has an active policy with 
regard to external cephalic version, this may have affected the rate of 
noncephalic presentations in this study.  
To date only one study, albeit with low epidemiological power, showed a 
relation between maternal thyroid function and breech presentation.80  
Motor skills in children with congenital hypothyroidism were reported to be 
significantly worse in children with high TSH or low T4-values on newborn 
screening compared to those with normal TSH values.81,82 Suboptimal maternal 
thyroid hormone supply has also been related to neonatal motor deficits.70-76 
Since breech presentation has also been linked to motor impairment, one may 
suggest that - if suboptimal maternal thyroid function is related to breech - the 
neonatal consequences of breech presentation could be explained via the 
thyroid hormone pathway.  
Moreover, since suboptimal maternal thyroid hormone supply has been related 
to behavioural problems such as autism and ADHD83,84, and breech presentation 
has also been linked to autism and ADHD5,36,37, it might be suggested that  the 
common link between behavioural problems and breech presentation could be 
explained in terms of thyroid hormone dysfunction. 
 
Therefore the first aim of this thesis was to investigate a possible relationship between 
maternal thyroid function and breech presentation. Furthermore, we investigated a 





1.4. Attitude towards breech presentation 
 
1.4.1. Caesarean Section (CS) 
In the Netherlands, vaginal delivery in case of breech presentation used to be 
common practice: roughly 25% of all term breeches were delivered by planned 
CS, 25% by CS after a trial of labour and 50% were delivered vaginally. After 
publication of one randomized trial “Term Breech Trial” (TBT) in 2000 a 
dramatic policy change occurred. In this study it was concluded that planned CS 
was better than planned vaginal birth for the term breech foetus, while serious 
maternal complications were similar between both birth groups.85 
Within 2 months following publication of the TBT the total CS rate for term 
breeches increased from 50 to 80%, all of this as a direct result of an increase in 
planned elective CS from 20-50%.86 International guidelines concluded that 
“planned vaginal delivery of a term singleton breech may no longer be 
appropriate” and that external cephalic version should be attempted “whenever 
possible”.87 In 2004 a follow-up study of the TBT birth cohort found no 
differences in maternal and infant outcomes of the planned CS group versus the 
vaginal delivered group, 2 years after delivery.88 The TBT has, since, been 
criticized. In 2006, the ACOG revised their guidelines to incorporate the new 
findings, recommending that “the decision regarding mode of delivery should 
depend on the experience of the health care provider, while continuing to 
endorse external cephalic version whenever possible”.89 
Also the Dutch and Canadian societies of obstetricians and gynaecologists 
currently state that with careful case selection and labour management of 
breech deliveries, a level of safety similar to elective CS may be achieved.24,90 
 
1.4.2. External Cephalic Version 
External cephalic version (ECV) is the manipulation of the foetus, through the 
maternal abdomen, into a cephalic presentation.  
 
1.4.2.1. History 
ECV has been practiced since the time of Hippocrates.91 ECV almost became 
extinct in the 1960s after several reports suggested high foetal complication 
rates associated with version maneuvers. In these studies general anesthesia was 
used, and preterm infants were included to improve the chances of success.92 In 
1974 Salinger and Müller-Holve suggested that ECV be performed under 
tocolysis after 37 weeks gestation and after screening with ultrasound and foetal 
cardiotocography (CTG).93 Subsequent studies from the 1980s showed that 
successful ECV could be achieved in a substantial proportion of term breech 
pregnancies with a low risk of complications. Recent randomized controlled 
trials demonstrate that ECV at or near term effectively reduces the risk of 




ECV has now become common practice. Publication of the Term Breech Trial85 
increased the popularity of ECV substantially.  
 
1.4.2.2. Procedure 
Various ECV procedures have been reported but have not been compared in 
randomized trials. In general terms, the procedure is as follows: clinical 
examination and ultrasound examination is performed to confirm the 
presentation, type of breech, placenta location and to assess the amniotic fluid 
index, and, preferably, to rule out the presence of a cord around the neck. 
Patients are usually asked to empty their bladder before the ECV. 
Prior and immediately after the procedure, foetal heart rate monitoring (CTG) 
is performed to confirm foetal well-being. The patient is placed in 
Trendelenburg position (bed tilted in 20 degrees head down position). Usually, 
only one operator performs the ECV and he/she stands on the side of the 
patient in the direction of version of the foetal head. Gel or powder is spread 
on the abdomen to facilitate hand movement and to be gentler to the skin. The 
breech is first disengaged by gentle pressure on both sides of the presenting 
part with the palm of the hand.94 Tocolysis to relax the uterus may or may not 
be administered. Slight back-and-forth movement between the two hands may 
help promote foetal movement. Generally, a forward roll is used to rotate the 
baby. A backward flip may be indicated if the spine lies directly anterior.95 
Simultaneously with the ECV, the foetal heart rate is registered intermittently, 
leading to interruption of the procedure if bradycardia occurs. In general, the 
procedure takes up to 5 minutes per attempt, with a maximum of 3-4 attempts 
in one session. Anti-D immune globulin (1000 IE) is administered to Rh(D)-
negative women who undergo ECV. 
 
1.4.2.3. Inclusion and exclusion criteria of ECV 
All women with a singleton term breech pregnancy should be offered ECV.90,96,97 
There are, however, a few important contra-indications, such as ante partum 
hemorrhage within the last 7 days, abnormal foetal heart rate pattern, if 
caesarean delivery is indicated irrespective of foetal presentation, major uterine 
anomaly, ruptured membranes, multiple pregnancy, severe maternal 
hypertension, or the mother carries the Human Immunodeficiency Virus. 
Some contra-indications may in fact be ‘relative’ contra-indications, and the risks 
and benefits of ECV should be individualized. These cases are small-for-
gestational age foetuses (less than 10th percentile), oligohydramnios, mild 




Obstetric invasive procedures can lead to foetomaternal hemorrhage (FMH). A 




prospective observational study in which a Kleihauer-Betke test was done in 
1311 women before and after ECV showed an FMH incidence of 2.4%, with a 
0.8% incidence of FMH greater than 1.0 ml and a 0.1% incidence of FMH greater 
than 30 ml of foetal blood. The risk of FMH was not influenced by parity, 
gestational age, body mass index, number of version attempts, placental location 
or amniotic fluid index. Furthermore, the occurrence of FMH was not related to 
foetal heart decelerations during the procedure.99 
-Other complications 
Complications after ECV, such as placental abruption, cord prolapse, foetal 
heart rate abnormalities and stillbirths are well-recognized but uncommon.  A 
systematic review revealed the following incidence figures: transient abnormal 
heart rate patterns (5.7%), persistent pathological CTG (0.37%), vaginal bleeding 
(0.47%), placental abruption (0.12%), emergency caesarean sections ( 0.4%) and 
perinatal mortality (0.1%).98 A recent meta-analysis confirmed that serious 
complications are rare and not related to foetal position after ECV.100 
Therefore, ECV is stated as a safe procedure. 
-Caesarean scar 
Previous caesarean delivery (CD) is considered as a relative contra-indication 
for an ECV attempt despite the absence of serious complications or risks.11 The 
risk of uterine rupture in patients with previous CD has not been determined. 
In a review of 5 studies investigating ECV after previous CD (n=166), 76% of the 
cases had favourable foetal and maternal outcomes. The results of ECV after a 
previous CD are, therefore, encouraging with a substantial success rate and a 
high probability of future normal vaginal delivery in more than 85% of cases.101  
 
1.4.2.5. Success rates and Effectiveness of ECV 
-Success rates 
Success rates for ECV range between 30 and 80%.97 Success rate figures from 
Dutch studies vary between 25 and 42%.102-107 These differences in success rates 
can partially be explained by differences in ethnicity (i.e., tendency to postpone 
breech engagement in the pelvic brim in Africo Americans) and selection bias 
(i.e., pre-selection of “favorable” ECV attempts).    
-Effectiveness 
ECV reduces both the number of breech presentation in labor (RR=0.42, 95%CI 
0.35-0.50) and the number of caesarean sections (RR=0.52, 95%CI 0.39-0.71).11 
These favourable statistics have led the American College of Obstetricians and 
Gynecologists (ACOG), the Royal College of Obstetricians and Gynaecologists 
(RCOG), the Royal Australian and New Zealand College of Obstetricians and 
Gynaecologists (RANZCOG) and the Dutch association of Obstetricians and 
Gynaecologists (NVOG) to recommend ECV as the best method to reduce the 
number of breech presentations and breech deliveries at term.90,96,97,108 
The application of ECV leads to considerable cost savings in the management of 




-Spontaneous version after (un)successful ECV 
Spontaneous version rates for nulliparous women of less than 5 % are reported 
both for unsuccessful 98,111,112 and successful ECV attempts.112,113  
The same factors thought to affect spontaneous version can potentially impede 
successful ECV treatment. The reported spontaneous version rates after 
(un)successful ECV, therefore, are higher (up to 12,5%) in multiparous women 
and in women with abundant amniotic fluid.114  
 
1.4.2.6. Determinants of success of ECV 
Several factors have been associated with successful ECV outcome including 
multiparity, non-frank breech, non tense uterus, non-anterior placenta location, 
higher birth weight, non–Caucasian ethnicity, amniotic fluid index > 7cm, normal 
body mass index, palpable foetal head, non-posteriorly located spine and non-
engagement of the breech.104,115-118 
Several prognostic models or scoring systems have been proposed, but, so far, 
none of these models/systems have proven to be satisfactory due to their 
limited clinical impact.116,119-121  
-Influence of gestational age 
Non-engagement of the breech is an important clinical factor interfering with 
ECV success. Therefore, ECV between 34 to 35 weeks gestation may have 
some advantage over ECV at 37 weeks or later, especially in nulliparous women.  
A multicentre randomized controlled trial (n = 233) included nulliparous 
women with any breech presentation and multiparous women with a frank 
breech presentation. ECV was initiated between 34 weeks and 36 weeks in the 
early group (n = 117); and between 37 weeks and 38 weeks in the delayed 
group (n = 116).122 Although not statistically significant, a 9.5% higher decrease 
in the rate of breech presentation at birth, and a 7% higher decrease in the 
caesarean section rate was found in the early ECV group compared with the 
delayed ECV group.122,123 Clearly, replication studies with adequate sample sizes 
are needed to further determine the possible benefit of initiating ECV prior to 
term. One international multicentre trial is currently in progress: The Early 
ECV2Trial, Canada (www.utoronto.ca/miru/eecv2).123 
-Influence of tocolytics 
The Cochrane database states that the use of tocolytics (beta-adrenergic drugs) 
in ECV reduces the failure rate of ECV. Whether tocolysis should be used 
routinely, or selectively in case of ECV failure, has as yet not been adequately 
addressed.124 
*Beta-adrenergic drugs  
The most widely used tocolytics are beta-adrenergic drugs such as salbutamol, 
ritodrine, hexoprenaline or terbutaline. These drugs are given intravenously or 
by inhalation. Because of the sometimes troublesome side-effects for mother 
and baby (i.e., tachycardia, tremor, anxiety, palpitations, sweating, retrosternal 




countries125, other tocolytic drugs are often used such as nitroglycerine, 
nifedipine and atosiban. 
 *Nitroglycerine 
The Cochrane review states that nitroglycerine should not be used for ECV 
because of increased side-effects, no evidence of effectiveness compared with 
placebo, and a trend towards lower effectiveness than with beta-stimulants.124 
However, a recent randomized controlled trial in 126 women showed higher 
ECV success rates in nulliparous women when using nitroglycerine intravenously 
titrated.125 It is, thus, possible that titration of this drug on an individual basis 
may yield superior results compared to a standard dose of nitroglycerin. 
*Nifedipine 
Three randomized controlled trials comparing the effect of oral nifedipine and 
beta-mimetics reported comparable ECV success rates for both drugs, albeit 
with fewer side effects for nifedipine.126-128 However, use of oral nifedipine in a 
randomized, double-blind, placebo-controlled trial in 310 women did not 
improve the success rate in ECV.102  
*Atosiban 
Experience with the use of atosiban (oxytocin antagonist) in ECV is limited to 
one small retrospective study in 38 women. The success rates were similar to 
data reported in the literature, but maternal side effects were less compared to 
other commonly used drugs.129  
-Influence of regional anesthesia 
Previous standard protocol dictated that no anesthesia should be employed for 
ECV, as pain is a reason to discontinue the attempt.44 Also Neiger et al. 
discouraged the use of neuraxial techniques out of fear of injuring the foetus by 
applying too much force.130 Other potential adverse effects of regional analgesia 
include a fall in blood pressure and headache.131 
In recent years however, there has been a renewed interest in the use of 
regional anesthesia to facilitate ECV. A meta-analysis showed that regional 
anesthesia can improve the success rate of ECV (RR=1.5, 95% CI 1.12-1.98).132 
A prospective randomized controlled trial in 70 women confirmed these 
results.133  
Despite these favorable results, it is difficult to draw definite conclusions 
regarding the use of regional anesthesia because of differences in study design 
and patient population in the various randomized control trials.131 
-Influence of experience  
Some authors have suggested that ECV success is not dependent on experience 
and clinical skills of the practitioner134-137, whereas others claim the 
opposite.104,138,139 There is certainly a learning process associated with 
performing ECV. Analysis of 80 consecutive ECV cases performed by one 
obstetrician without previous ECV experience showed that at first the learning 




According to the Australian and British guidelines ECV should be performed by 
suitably trained health professionals.97,140 Furthermore, accumulating ECV 
experience allows the practitioner to optimize the procedure through 
introducing new features and techniques. 
 
The second aim of this thesis was, therefore, to evaluate the determinants/potential 
prognostic variables affecting the outcome of ECV in breech presentation.  
The third aim of this thesis was to investigate whether the ECV protocol/procedure 
could be improved, by implementing a number of process policy guidelines.  
 
-Influence of umbilical cord length 
Umbilical cord length (UCL) is a marker of foetal mobility.63-65 Since UCL is 
shorter in breech than in cephalic presentation46,58-62, it might be hypothesised 
that UCL, in turn, may affect ECV outcome.  
Furthermore, the literature shows that after successful ECV with cephalic 
presentation at delivery, the rate of vaginal delivery is substantially lower 
compared to women with cephalic presentation at birth without a history of 
breech.141-145 Therefore, it might also be hypothesised that UCL could affect 
delivery mode, even after successful ECV. 
-Influence of maternal thyroid function 
Maternal thyroid function has an impact on foetal motility146 and placental 
growth147, both determinants of successful ECV. Therefore, it could be 
hypothesized that ECV outcome is influenced by thyroid function. 
Until now, no studies have been published addressing the possible effects of 
maternal thyroid function on ECV outcome. 
 
Therefore a fourth aim of this thesis was to investigate whether women with 
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Chapter 2: Outline of the thesis 
II.1. Questions 
The aim of this thesis was to address two different types of questions. 
Firstly, with regard to maternal thyroid function during pregnancy: 
• The effect on foetal presentation 
• The effect on neonatal thyroid function assessed at screening  
Secondly, with regard to ECV outcome: 
• Which determinants affect ECV outcome? 
• What is the impact of ECV- performed according to a standardized protocol 
in an outpatient clinic- on delivery mode? 
• What is the effect of implementing a number of process policy guidelines 
(protocol), on ECV success rate? 
• Is there a relationship between maternal thyroid function during gestation and 
successful ECV? 
 
II.2. Study design 
II.2.1. The Kempen study 
A prospective follow-up study throughout pregnancy in healthy Dutch 
Caucasian pregnant women was performed from 12 weeks gestation onwards, 
until term (≥ 37 weeks) delivery. This study was approved by the Medical Ethical 
Committee of Máxima Medical Centre Eindhoven/Veldhoven, The Netherlands. 
All women who booked for antenatal control at 12 weeks gestation in five 
community midwife practices were invited for maternal thyroid function 
screening. Women who consented to participate were followed at 24 and 36 
weeks gestation to assess thyroid function, obstetrical parameters and foetal 
presentation by ultrasound (36 weeks). 
The primary outcome measure was the relationship between maternal thyroid 
function at each pregnancy trimester and foetal presentation at 36 weeks 
gestation. A secondary outcome measure was the relationship between 
maternal thyroid function at each pregnancy trimester and neonatal screening 
results. 
 
II.2.2. Retrospective ECV and Prospective EBIS (Eindhoven Breech 
Intervention Study) 
In 2003 a standardized ECV protocol was developed for the outpatient 
obstetric clinic at the Catharina Hospital in Eindhoven, The Netherlands. A 
retrospective study design was used to analyze all ECV’s performed from 
January 2004 until July 2006. The aim of the study was to identify the 
determinants affecting ECV outcome in breech presentation, and to evaluate the 
impact of ECV performed according to a standardized protocol on delivery 
mode. 
Over this 3-year period a standardized ECV protocol was developed, evaluated, 
and further optimized/modified/adapted. The changes in the original protocol 
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could be summarized according to the four R’s: regularity, routine, release and 
relaxation. ECV was regularly performed (every week at fixed dates) by two 
clinicians from a team of 4 experienced obstetricians, who were released from 
other obstetrical/ medical activities. Tocolysis (Atosiban, 6,75 mg. intravenously) 
was administered routinely. After implementing this modified protocol as 
”process policy guidelines”, the effect on ECV success rate was prospectively 
evaluated from the 1st  of January 2007 to the 31st of July 2008. 
This prospective study was approved by the Medical Ethical Committee of the 
Catharina Hospital.  
Finally, to investigate whether maternal thyroid function is related to ECV 
outcome, a prospective study in ECV patients was performed. This prospective 



























































Maternal thyroid function during gestation 









To study the relationship between suboptimal maternal thyroid function during 
gestation and breech presentation at term. 
 
Design 
Prospective follow-up study during three trimesters of gestation. 
 
Patients: A total of 1058 Dutch Caucasian healthy pregnant women were 
prospectively followed from 12 weeks gestation until term (> 37 weeks) 
delivery. 
 
Measurements: Maternal thyroid parameters (TSH, FT4 and TPO-Ab) were 
assessed at 12, 24 and 36 weeks gestation as well as foetal presentation at term. 
 
Results 
At term, 58 women (5.5%) presented in breech. Compared with women with 
foetuses in the cephalic position, those women who presented in breech at 
term had significantly higher TSH concentrations, but only at 36 weeks gestation 
(p = 0.007). No between group differences were obtained for FT4 level at any 
assessment. The prevalence of breech presentation in the subgroup of women 
with TSH ≥ 2.5 mIU/l (90th percentile) at 36 weeks gestation was 11%, 
compared to 4.8% in the women with TSH < 2.5 mIU/l (p = 0.006). Women 
with TSH below the 5th percentile had no breech presentations. Breech position 
was significantly and independently related to high-normal maternal TSH 
concentration (≥ 2.5 mIU/l) at 36 weeks gestation (OR: 2.23, 95% CI: 1.14 -
4.39), but not at 12 and 24 weeks gestation. 
 
Conclusion 
Women with TSH levels above 2.5 mIU/l during end gestation are at risk for 
breech presentation, and as such for obstetric complications. 
 





Breech presentation at term is the most common abnormal foetal presentation 
and is associated with neonatal and maternal morbidity and mortality. The 
incidence of breech presentation decreases with term of gestation from 
approximately 16% at 32 weeks to 3-5% at 40 weeks gestation.1 Many 
aetiological factors associated with breech presentation have been described 
previously, including, among others, prematurity, low birth weight, primiparity 
and smoking during pregnancy.2-5 As these factors explain only 15 % of the 
variance of breech presentation,6,7 further research into the mechanisms of 
breech presentation is needed.8 
Ample evidence suggests a relationship between (sub)clinical thyroid dysfunction 
during gestation and impaired obstetrical outcome.9-15 However, these studies 
mostly refer to overall impaired obstetric outcome with little emphasis on 
specifics including foetal presentation at term. A previous study of our group 
suggested a relationship between low maternal FT4 at 12 weeks gestation and 
breech presentation.16 The number of breech cases, however, was very low due 
to the small sample size, and the sample was highly selected according to first 
trimester FT4 levels, which prevented us from looking at other thyroid 
parameters such as TSH. 
The current study examines whether maternal thyroid hormone function during 
gestation is related to foetal position in a large sample of pregnant women from 
the general population, who were prospectively followed during gestation. The 
primary outcome measure was the relationship between maternal thyroid 




Over a period of 2 years, 1507 Dutch Caucasian pregnant women in five 
community midwifery practices, living in and around the city of Eindhoven (The 
Netherlands), were invited to participate at the time of their first antenatal visit 
at 12 weeks gestation. Seventy-nine percent (n = 1190) of the women 
consented to participate. Non-responders did not differ from the responders 
with regard to age, parity, or educational level. Women on thyroid medication 
(n = 10), those with known clinical hyperthyroidism (n = 8) or hypothyroidism 
(n = 2) at screening, those who became pregnant after hormonal stimulation (n 
= 8), those with multiple pregnancy (n = 8), as well as women with Type 1 
diabetes (n = 5) were excluded. 
Therefore, 1149 women were eligible for further participation and were 
followed up at 24 and 36 weeks gestation. Because spontaneous change of foetal 
position at term was an outcome measure, four cases with successful external 
cephalic version were excluded. Moreover, 11 women whose data were 
incomplete and an additional four mothers whose babies were born with severe 




were excluded. Of the remaining 1130 women, 72 delivered prior to 37 weeks 
gestation. Because breech position before term is not regarded as an abnormal 
foetal position, these women were excluded. Consequently, data analyses in the 
current study refer to a final sample of 1058 women who delivered at term (i.e., 
> 37 weeks gestation), and in whom thyroid function was assessed in all three 
trimesters. None of these women were treated for thyroid disease during 
gestation. Eight of the 1058 women (0.8%) developed gestational diabetes. 
This study was approved by the Medical Ethics Committee of Máxima Medical 
Centre in Eindhoven/Veldhoven, The Netherlands. 
 
Assessments 
Term was assessed in two ways: from the date of the last menstrual period and 
from an ultrasound scan in the first trimester. If there was a discrepancy of 
more than 7 days between these two measurements, a second ultrasound was 
performed within 2 weeks to re-assess gestational age. Gestational age was 
expressed in weeks and days. Foetal position at birth was classified as cephalic 
or breech (i.e., complete/incomplete or frank breech). Possible confounders 
such as previous obstetrical history (parity, previous Caesarean section) 
demographic features and life style habits (smoking, alcohol intake, BMI) were 
carefully assessed during follow-up. 
 
Thyroid parameters 
Thyrotrophin (TSH), free thyroxine (FT4) and auto-antibodies to thyroid 
peroxidase (TPO-Ab) were assessed at 12, 24 and 36 weeks gestation. TSH was 
measured using a solid-phase, two-site chemiluminescent enzyme immunometric 
assay (IMMULITE Third generation TSH, Diagnostic Products Corporation, Los 
Angeles, USA). The inter-assay coefficients of variation were 5.0% and 4.4% at 
concentrations 0.22 mIU/l and 2.9 mIU/l, respectively. FT4 concentration was 
also measured by means of a solid-phase immunometric assay (IMMULITE FT4). 
The inter-assay coefficients of variation for this technique were 6.7% and 4.4% 
at concentrations of 11.6 pmol/l and 31.5 pmol/l, respectively. Reference ranges 
for TSH and FT4 were: 0.4 - 4.0 mIU/l and 10 - 24 pmol/l, respectively. The 
IMMULITE TPO-Ab kit was used for the determination of antibodies against 
thyroid peroxidase (TPO). The inter-assay coefficients of variation for this 
analysis were 9% and 9.5% for concentrations of 40 kU/l and 526 kU/l, 
respectively. The anti-TPO assay was standardized in terms of the International 
Reference Preparation for anti-TPO MRC 66/387. Women with TPO-Ab 
concentrations higher than 35 kU/I at 12 weeks gestation were regarded as 
antibody positive. 
 





Statistical analysis was performed using the Statistical Package for the Social 
Sciences Version 16.0. (SPSS). Initial analyses described the sample using means, 
standard deviations and frequencies. Kolmogorov-Smirnov tests revealed a non-
normal distribution of FT4 and TSH in the sample at all assessments. Therefore, 
FT4 and TSH were compared in the breech versus cephalic presentation groups 
using Mann-Whitney U-tests. Associations between the prevalence of elevated 
maternal thyroid antibodies (TPO-Ab >35) and foetal presentation at term were 
analysed using chi-square tests. Differences in the prevalence of breech 
presentation were also examined using chi-square tests to compare groups 
based on TSH cutoffs and/or gestation. Determinants of breech presentation 
were analysed using single and multiple logistic regression analysis (OR, 95% CI). 
 
Results 
Throughout gestation, a decrease in mean FT4 was paralleled by an increase in 
mean TSH (table 1). The number of women with elevated TPO-Ab 
concentrations decreased towards term. Table 2 shows the differences in 
thyroid parameters between the 58 women (5.5%) who presented in breech 
position at term versus the remaining 1000 women who presented in cephalic 
position. At 36 weeks gestation, women with foetuses in breech position had 
significantly higher TSH concentrations compared to those with foetuses in 
cephalic position (Mann-Whitney U-test, Z = 2.7, p = 0.007) whereas there 
were no differences in TSH concentrations at 12 and 24 weeks gestation. FT4 
was not significantly related to breech presentation at any trimester. 
Similarly, groups did not differ in terms of prevalence of women with elevated 
TPO-Ab concentrations (data not shown). 
In the absence of accepted reference values of normal thyroid function during 
pregnancy, the 5th, 10th, 90th and 95th percentiles cutoff points for TSH 
concentration at 36 weeks gestation were calculated. These values were: less 
than the 5th (< 0.51 mIU/l), n = 54; for the 5 - 10th percentiles (0.51 - 0.71 
mIU/l), n = 54; for the 90 - 95th (2.50 - 2.89 mIU/l), n = 49; and for the 95th 
percentile (> 2.89 mIU/l), n = 59. Figure 1 shows the percentage of women who 







Table 1: Characteristics of 1058 term (≥ 37 weeks gestation) pregnant women in whom 
thyroid parameters were assessed in all three trimesters. 
  Mean (SD) N (%) 
Demographic features     
Age (19 - 43) 30.6 (3.5)   
Marital status     
 With partner   1037 (98) 
 Single   21 (2) 
Educational level     
 Low   85 (8) 
 Middle   476 (45) 
 High   402 (38) 
 Academic   95 (9) 
Life style habits     
 Smoking   127 (12) 
 Alcohol intake   137 (13) 
Body mass index     
 <20   741 (7) 
 Between 20 and 25   636 (60) 
 Between 26 and 30   234 (22) 
 >30   117 (11) 
Obstetrical features     
Parity     
 Primiparity   508 (48) 
 Multiparity   550 (52) 
Previous miscarriage in life   212 (20) 
Term of gestation in weeks (37.0 - 42.9) 39.9 (1.2)   
Foetal presentation at delivery     
Cephalic   1000 (94.5) 
Breech   58 (5.5) 
Mode of delivery     
Spontaneously   699 (66) 
After stimulation   148 (14) 
Ventouse   95 (9) 
Primary Caesarean section   53 (5) 
Secondary Caesarean section   63 (6) 
Neonatal outcome     
Male sex   550 (52) 
Birth weight in grams (1940 - 5170) 3528 (482)   
Thyroid parameters     
12 weeks      
 FT4 pmol/l (9.4 - 26) 16.1 (2.5)   
 TSH mIU/l (0.01 - 9.25) 1.2 (0.8)   
 TPO-Ab >35 kU/l   91 (9) 
24 weeks FT4 pmol/l (8.4 -23) 13.8 (2.0)   
 TSH mIU/l (0.01- 6.2) 1.4 (0.7)   
 TPO-Ab >35 kU/l   79 (8) 
36 weeks      
 FT4 pmol/l(7.2 - 21) 13.3 (2.0)   
 TSH mIU/l (0.5 - 5.4) 1.5 (0.7)   
 TPO-Ab >35 kU/l   70 (7) 
 





Table 2: Median and range of FT4 and TSH in 58 women with breech presentation 
compared to 1000 women with cephalic presentation at term 
 FT4 (pmol/l) TSH (mIU/l) 
 cephalic breech cephalic breech 
12 weeks 15.9 9.1 - 27.9 15.8 12 - 21.1 1.09 0.01 - 6.20 1.06 0.39 - 5.10 
24 weeks 13.8 8.4 - 23.0 13.5 9.0 - 18.4 1.19 0.01 - 5.70 1.29 0.40 - 3.50 
36 weeks 13.2 7.2 - 24.6 13.3 9.8 - 17.5 1.30 0.05 - 5.01 1.60 0.58 - 5.40 * 
* = significantly different, Mann-Whitney U-test, p = 0.007 
 
With regard to the 90th and 95th percentile TSH groups at 36 weeks gestation, 
11% and 14% of the women presented in foetal breech position at delivery, 
while there were no cases of breech presentation in the lowest 5th percentile 
TSH group (χ2 [3]: 9.7, p = 0.02). The prevalence of breech presentation in the 
subgroup of women with TSH ≥ 2.5 mIU/l (> 90th percentile) was 11% (12/108), 
compared to 4.8% (46/950) in the women with TSH < 2.5 mIU/l (χ2 [1]: 7.5, p = 
0.006). When similar cutoff categories were made for FT4, no relation between 
FT4 and breech presentation was found. 
 
Figure 1. Percentage of breech presentation at term, according to different percentile 
categories of maternal TSH at 36 weeks’ gestation 
 
 
Table 3A shows the unadjusted odds ratios using logistic regression (OR, 95% 
CI) with breech position at birth as the dependent variable: nulliparity, birth 
weight and high-normal TSH (≥ 2.5 mIU/l) at 36 weeks gestation were all 




oddsratios using multiple logistic regression analysis, again with breech 
presentation at birth as the dependent variable. High-normal TSH levels at 36 
weeks gestation, nulliparity, birth weight and smoking, were all significantly 
related to breech presentation. 
Elevated TPO-Ab concentrations at 36 weeks gestation were not related to 
breech presentation. Of the 108 women with high-normal TSH levels at 36 
weeks gestation, 17 (16%) had a history of parental thyroid disease, compared 
to 66 women (6.6%) in the group with low TSH levels (χ2 [1]: 10.4, p = 0.001). 
Similarly, of the 108 women with high-normal TSH at 36 weeks gestation, 20 
(18%) had elevated TPO-Ab at 12 weeks gestation, compared with 66 (7%) in 
those with TSH < 2.5 mIU/l (χ2 [1]: 15.1, p < 0.001). 
Finally, of the 83 women with a history of parental thyroid disease, 20% had 
elevated TPO-Ab at 12 weeks gestation, compared to 8% of the women with no 
family history of thyroid disease (χ2 [1]: 14.3, p < 0.001). None of the women 
with gestational diabetes had an elevated TSH concentration at 36 weeks 
gestation. 
 
Table 3: Logistic regression analysis (dependent variable: breech presentation at term). 
 OR 95% CI 
3A. Unadjusted oddsratios   
Nulliparity 2.38 1.12 - 4.34 
Smoking during gestation 1.88 0.67 - 5.55 
Alcohol intake 1.25 0.60 - 2.61 
High BMI 0.99 0.94 - 1.05 
High birth weight 0.93 0.92 - 0.96 
High maternal age 1.03 0.96 - 1.11 
Female sex 0.92 0.54 - 1.56 
Low educational level 1.05 0.84 - 1.32 
TPO-Ab > 35 kU/l at 36 wks 1.45 0.78 - 2.20 
High-normal TSH (≥ 2.5 mlU/ml) at 36 wks 1.55 1.14 - 2.10 
   
3B. Adjusted oddsratios   
Nulliparity 2.71 1.17 - 5.50 
Smoking during gestation 2.97 1.23 - 7.69 
Alcohol intake 1.22 0.77 - 2.82 
High BMI 1.04 0.92 - 1.07 
High birth weight 0.97 0.93 - 0.99 
High maternal age 1.04 0.96 - 1.13 
Female sex 0.83 0.39 - 1.78 
Low educational level 1.05 0.78 - 1.40 
TPO-Ab > 35 kU/l at 36 wks 1.85 0.88 - 3.21 
High-normal TSH (≥ 2.5 mIU/ml) at 36 wks 2.23 1.14 - 4.39 
 
 





In the current study, breech position at birth was found to be related to 
maternal thyroid hormone status during late pregnancy. Not only was breech 
delivery almost 2.5 times more common in women with TSH levels at or above 
2.5 mIU/l, regression analyses also confirmed elevated maternal TSH 
concentrations at 36 weeks gestation as a key predictor for breech 
presentation. High TSH levels were significantly associated with increased TPO-
Ab concentrations as well as a history of thyroid disease in the parents. None of 
the women with TSH levels below the 5th percentile presented in breech 
position at term. 
The current paper is among the first in which a possible relationship between 
maternal thyroid function and foetal position at birth was investigated. Our 
research group previously found breech presentation at term to be related to 
FT4 at 12 weeks gestation16 in a smaller study using a highly selected sample of 
women (i.e., those with FT4 levels below the 10th percentile matched to those 
with an FT4 between the 50-90th percentile). However, a relation between 
breech position and TSH could not be examined in that sample, because the 
women were selected on the basis of FT4. In contrast, the current study used a 
much larger, unselected sample drawn from the general population, and we 
found high-normal elevated maternal TSH rather than low maternal FT4 to be 
the key predictor for breech presentation. In this unselected sample, 18% of the 
women with FT4 below the 10th percentile at 12 weeks gestation had TSH 
above the 90th percentile at 36 weeks gestation, compared to 6% of the women 
with an FT4 between 50-90th percentile (i.e., cutoff used in previous study). It is 
possible that the low first trimester FT4 in the previous study actually reflected 
high-normal TSH in late gestation. A recent paper, however, reports that free 
T4 immunoassays during gestation are less reliable compared to non-pregnant 
situations.17 Future research is needed to detect the most appropriate tool for 
screening of maternal thyroid function during gestation. 
The current findings are consistent with data of a large retrospective study in 
which elevated TSH (and not low FT4) was related to poor obstetric 
outcome.14 The cutoff used in the current study to define high-normal TSH (≥ 
90th percentile, 2.5 mIU/l) at 36 weeks gestation, was even lower than the cutoff 
of 3.0 mIU/l as recently recommended by the American Endocrine Society in 
pregnant women with hypothyroidism who are treated with thyroid hormone 
(in the absence of evidence-based reference ranges for TSH throughout 
gestation).18  
Consequently, it may well be that even women with TSH levels ≥ 2.5 mIU/l are 
already at risk for obstetrical complications. The increase of TSH during late 
gestation is generally explained by physiological adaptation mechanisms during 
pregnancy - mainly based on an increased iodine need - as summarized 
elsewhere.19 It is well known, that women with elevated TPO-Ab 




current study, whereas a direct link between TPO-Ab and breech presentation 
could not be demonstrated. Moreover, the T3/T4 ratio might be changed, 
resulting in FT3 changes with a possible effect on TSH. Unfortunately, FT3 was 
not assessed in the current study.  
How can the observed relationship between maternal TSH and foetal breech 
presentation be explained? The TSH receptor (TSHR) is expressed not only in 
the thyroid, but also in adipose tissue, brain, orbital tissue, lymphocytes and 
bone.20 Evidence is accumulating for direct effects of TSH via the TSHR on these 
tissues.21 However, until now, no TSHR has been described in the uterus. One 
could argue that elevated maternal TSH exerts an effect on uterine 
contractions. Empirical evidence regarding such a direct effect is, however, 
scarce. Only two studies were found, one showing reduced responsiveness to 
uterine agonists in hypothyroid rats,22 and another concluding that this might be 
caused by a reduction in uterine myometrial Ca2+ channel function.23 Uterine 
contractions are important for final cephalic presentation at term as has been 
suggested by a large Norwegian study including over 45,000 breech cases.3 The 
finding in the current study that none of the women with TSH levels within the 
lowest 5th percentile presented in breech position may also be interpreted as 
indicative of a direct impact of maternal TSH on uterine contractions and, 
hence, on breech presentation. Such a presumed relationship would be 
consistent with recent findings by Casey et al. who showed that women with 
sub-clinical hyperthyroidism (TSH < 2.5th percentile and FT4 within normal 
range) did not show an increased risk for obstetric problems in general.24 
Other factors in the current study, which were found to be related to breech 
presentation, have been described previously, such as nulliparity, birth weight 
(interfering with gestational weight) and smoking (affecting foetal muscle tone 
and in utero foetal motility).2-5 Several limitations of the study need to be 
mentioned. First, although a large sample of over 1000 women was followed 
throughout gestation, the ultimate number of breech presentations was still 
relatively low. Another issue relates to the fact that other possible determinants 
of breech presentation such as umbilical cord length and amniotic fluid volume 
were not evaluated. 
Major strengths of the study include the rather strict time frame of thyroid 
hormone assessments and the careful follow-up of all women by one midwife 
(HW) who was kept blinded to thyroid hormone status. 
In conclusion, this study shows that in otherwise healthy women, high-normal 
levels of maternal TSH during late gestation are associated with breech 
presentation at term. Future strategies for minimizing breech presentation 
should, therefore, consider the role of maternal thyroid (dys)function, including 
T4 substitution during gestation in women with high-normal TSH. 
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Combined data sets of two prospective studies to obtain adequate 
epidemiological power. 
 
Patients: 1058 healthy pregnant women (58 breech, 1000 cephalic) and 131 
women who presented in breech at an obstetrical outpatient clinic.  
 
Measurements: Maternal thyroid parameters (TSH, FT4, TPO-Ab) and foetal 
presentation were assessed in both groups between 35-38 weeks gestation. 
Power calculations suggested that at least 148 breech cases were required. 
 
Results 
The characteristics of the women in breech in both samples were similar. 
Women in breech (n = 58+131) had significantly higher TSH (but not FT4) than 
those (n = 1000) with cephalic presentation (Mann-Whitney U, p = 0.003). 
Different cutoffs were used to define high TSH in the 916 TPO-Ab negative 
women with cephalic presentation: the 90th, 95th and 97.5th percentiles were 2.4 
mIU/l (n = 149), 2.7 mIU/l (n = 77) and 3.2 mIU/l (n = 37). The prevalence rates 
of breech presentation in these women were all higher compared to the 
prevalence of breech in women below these cutoffs (df = 1, p < 0.01). The RR 
of the 149 women with a TSH > 90th percentile (> 2.4 mIU/l) to present in 
breech was 1.82 (95% CI: 1.30 - 2.56). 
 
Conclusions 
Women with high-normal TSH at end term are at risk for breech presentation. 
Substantial evidence for a relation between breech presentation and 
neurodevelopmental delay exists. Since high TSH during gestation has also been 
linked to poor neurodevelopment, the relation between breech presentation 
and poor neurodevelopment might be thyroid-related.  
 




Breech presentation occurs in 3-5 % of term women and is associated with 
neonatal as well as maternal morbidity and mortality. Breech is often an 
indication for elective caesarean section (CS)1, which, in itself, constitutes a 
prominent risk factor for decreased reproductive health.2  According to a 
recent review, the currently known risk factors associated with breech 
presentation only account for up to 15 % of the variance.3  
We previously reported that women who presented in breech had higher TSH 
levels than those who presented in cephalic position.4 This study, however, was 
limited by small sample size. To overcome this limitation, the current study 
expanded on our previous findings by combining the breech cases (n = 58) from 
our initial study4 with a newly obtained larger sample of breech cases (n = 131). 
Moreover, we reviewed the literature on possible consequences of breech 




The current study combines two samples of pregnant women from the same 
area in the South-East of The Netherlands. The first sample comprises 1058 
pregnant women who were recruited between 2002 - 2004 for a follow-up 
study in which maternal thyroid status was assessed at 12, 24 and 36 weeks 
gestation.4 Foetal position was assessed by ultrasound between 35 - 38 weeks 
gestation. The second sample comprises 161 pregnant women who, between 
2007-2009, presented in breech at an obstetric clinic for an External Cephalic 
Version (ECV) attempt. Of these women, 151 were eligible and ultimately 141 
women consented to participate. Prior to the ECV attempt, obstetrical 
parameters were assessed and blood samples were taken. While term of 
gestation in this sample varied between 35 - 39 weeks, for the purpose of the 
current study only women with a term between 35 - 38 weeks (n = 131, 93%) 
were included.  
In both samples, women with twin pregnancies, on thyroid hormone 
replacement therapy, those with known auto-immune disorders (e.g., diabetes-
I), or those who became pregnant after hormonal stimulation, were excluded, as 
well as women with preterm birth (study 1). To avoid potential language 
problems only women of Dutch Caucasian background were included. This 
resulted in a total of 121 women who were excluded from the first sample and 
20 women from the second sample. 




Foetal presentation was assessed by ultrasound in study one by one researcher 





the ECV attempt. Breech position was categorized into complete, incomplete 
and frank breech. In all women a careful obstetrical history was taken.  
 
Thyroid parameters  
Thyroid parameters, free thyroid hormone (FT4), thyrotrophin (TSH) and 
thyroid peroxidase antibodies (TPO-Ab) were in the first sample assessed 
during the ultrasound visit at 35 - 38 weeks gestation, and in the second sample 
during the visit at the obstetrical outpatient clinic just before the ECV attempt. 
Only the third trimester TSH/FT4 assessments at 35 - 38 weeks in the first 
sample were taken into account and compared with the thyroid parameters of 
the women with a similar term seen in the ECV outpatient clinic. 
TSH was measured using a solid-phase, two-site chemiluminescent enzyme 
immunometric assay (IMMULITE Third generation TSH, Diagnostic Products 
Corporation, Los Angeles USA). FT4 (concentration was also measured by 
means of a solid-phase immunometric assay (IMMULITE Free T4). The 
IMMULITE Anti-TPO Ab kit was used for the determination of antibodies 
against thyroid peroxidase (TPO). The anti-TPO assay was standardized in 
terms of the International Reference Preparation for anti-TPO MRC 66/387. 
TPO-Ab concentrations higher than 35 kU/l were regarded as antibody positive.  
 
Statistical analysis 
Statistical analysis was performed using the Statistical Package for the Social 
Sciences (SPSS 17.0). First, a power calculation was performed. The TSH 
numbers at 36 weeks gestation of study one were log transformed and the 
difference (delta) in means between the women presenting in breech versus 
those presenting in cephalic position was calculated. With an alpha of 0.05 and a 
power of 0.8, it was calculated that the size of the breech group in the current 
study needed to be at least 148 women.  
Kolmogorov-Smirnov tests revealed a non-normal distribution of FT4 and TSH 
in the current sample. Therefore, group comparisons on FT4 and TSH used 
Mann-Whitney U-tests. T-tests (two-tailed) and chi-square tests were used for 
other group comparisons. Subsequently, we looked at different cutoffs for 




The characteristics of breech women in sample one (n = 58) and those in 
sample two (n = 131) were compared (table 1). As can be seen, there were no 
significant differences between the groups.  
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Table 2 shows the characteristics of the total group of breech women (58 + 131 
= 189) versus the women of sample one who presented in cephalic position (n 
= 1000). In the latter group, TSH and FT4 reference ranges were calculated 
(between the 2.5th and 97.5th percentiles) at 36 weeks gestation for those 
women who were TPO-Ab negative at 12 weeks gestation (n = 916). These 
ranges were: 0.42 - 3.2 mIU/l for TSH and 9.4 - 17.1 pmol/l for FT4. As can be 
seen in table 2, the women who presented in breech had significantly higher 
TSH levels compared to those who presented in cephalic position (Mann-
Whitney U, p = 0.003), while no between group differences were found for FT4 
(Mann-Whitney U, p = 0.62).  
 
Figure 1: Comparison of prevalence rate of breech presentation at 35 – 38 weeks between 
women above and below different percentile cutoffs of TSH (total group n = 1189, of which 
189 breech and 1000 cephalic presentations) 
 
Significantly more primiparous women were found among the breech-presenting 
women versus the cephalic-presenting women. Groups did not differ in terms of 
the prevalence of women with elevated TPO-Ab. Subsequently, for the overall 
group (n = 1189) different TSH cutoff values were defined in the TPO-Ab 
negative women with cephalic presentation: the highest 90th (> 2.4 mIU/l, n 
=149), 95th (> 2.7 mIU/l, n = 77) and 97.5th (> 3.2 mIU/l, n = 37) percentiles. 
Comparing prevalence rates above and below these cutoffs of TSH categories, 
breech-presenting women were significantly more prevalent than cephalic-
presenting women (25% versus 14%, 27% versus 15% and 35% versus 15%, p < 
0.01, figure 1). The number of women with elevated TPO-Ab in the group with 
TSH > 90th, the 95th and the 97.5th percentile was significantly higher compared 
to the number of women below these cutoffs: 14% versus 4.5%, 17% versus 5% 





pmol/l (in TSH > 3.2 mIU/l) versus 13.3 pmol/l (TSH <3.2mIU/l) or 13.4 pmol/l 
in women with a TSH < 50th percentile. 
 
When high TSH (> 97.5th percentile) and parity were entered into a logistic 
regression analysis, both were found to be significantly related to breech 
presentation (dependent variable): OR: 2.3, 95% CI: 1.2 - 4.9 and OR: 5.1, 95% 
CI: 3.4 - 7.5, respectively. The 37 women with a TSH > 97.5th percentile (> 3.2 
mIU/l) had a median TSH of 3.7 mIU/L with a range between 3.3 - 10 mIU/L, and 
13 presented in breech. Finally, women with a TSH > 90th percentile (> 2.4 
mIU/l) already had a 1.82 increased risk of breech presentation (RR: 1.82, 95% 
CI: 1.30 - 2.56). 
 
Discussion 
The current study combined the data sets of two studies in which the 
relationship between maternal thyroid status and foetal breech position was 
investigated. The present combined results obtained in 189 breech versus 1000 
cephalic cases were clear in showing that high-normal maternal TSH during 
pregnancy is related to increased rates of breech position. It is unlikely that this 
relationship has arisen by chance, given the 189 breech cases in this study which 
was substantially higher than the minimum group size of 148 suggested by the 
power calculations. In line with the literature, primiparity was significantly more 
prevalent in breech cases compared to cephalic cases.3 
In a recent large retrospective study elevated maternal TSH levels in both the 
first and second trimesters were not related to adverse obstetrical outcome.5 In 
contrast, another large retrospective study did report a relation between 
increased TSH and poor obstetrical outcome (without detailed reports on 
foetal position), with TSH being assessed between 12 and 24 weeks gestation.6 
How can the relation between high maternal TSH and breech position be 
explained? As discussed in a previous paper, one might speculate that TSH 
directly acts to modulate uterine contractility.4 Another (more indirect) 
explanation might be that high-normal maternal TSH reflects suboptimal 
maternal thyroid function, which, in turn, would affect maternal-foetal T4 
transfer, with impaired foetal neuromotor outcome as a final consequence. The 
finding that women with elevated TPO-Ab levels are especially at risk for high-
normal TSH levels does suggest that high-normal maternal TSH in these women 
is pathologic rather than physiologic (the latter, for example, to compensate for 
high T4 turnover by deiodinase activity of the placenta).     
In view of this latter explanation, several examples of delayed foetal neural 
maturation in breech pregnancies are worth addressing. First, the foetus, from 
24-35 weeks onwards changes position through sudden leg extensions and 
active whole body movements (kicking).7 These changes are caused through 
excitation of antigravity muscles, i.e. extensors of the body axis.8 This excitation 
is a result of the interplay between inhibitory and stimulatory influences 
generated in the reticular nuclei, cerebellum and motor cortex. One may 
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speculate that sub-optimal maternal thyroid function (reflected by high TSH) 
might affect the neural processes involved in changes of foetal position. 
Secondly, foetuses in breech position show different sensory experiences 
compared to those presenting in cephalic position.9 Although this was explained 
in terms of more amniotic fluid surrounding the head in breech, also this effect 
might have been due to suboptimal maternal-foetal thyroid hormone supply. In 
another study the development of lateralized head-position preference was 
found to be less pronounced in breech foetuses than in cephalic foetuses.10 
Although this may have been related to a smaller difference in stimulation 
between the left and right otoliths, inadequate thyroid hormone supply for 
development of the cochlear system might have been involved.11  
With regard to neonatal maturation, breech babies tend to be smaller12, have 
lower scores on neurological tests13,14,15 and are balance-impaired until the age 
of 12-18 months.16 Again, for all these findings inadequate maternal-foetal T4 
supply may have been an underlying etiological factor with regard to optimal 
neurodevelopment. A large cohort study reported a significant IQ delay in 20 
years old men born in breech compared to men born in cephalic presentation.17 
A similar IQ delay has been reported in children of women with high TSH 
during gestation.18 Finally, autism spectrum disorder has been found to occur 
more frequently in children born in breech position.19 Autism has also been 
linked to poor maternal thyroid function during gestation.20,21 
A limitation of the current study was that two different studies were combined. 
These studies, however, were performed in the same region, in women with 
similar characteristics, using identical thyroid assessments tests. Combining 
studies, however, also constituted a key strength, as it heightened the statistical 
power, thereby allowing a more accurate estimation of the relationship between 
high TSH and breech position. Other study strengths were its prospective 
design, and the fact that obstetric staff was blind to the thyroid status of the 
women.  
In conclusion, this study strongly suggests a relationship between high-normal 
maternal TSH and foetal position at end term. It also suggests that 
neurodevelopmental delay, which has been related to breech presentation at 
term, might in fact reflect sub-optimal maternal thyroid function during 
gestation. Because breech presentation is associated with neonatal as well as 
maternal morbidity and mortality, future prospective studies are needed to 
further elucidate the relation between high-normal maternal TSH and foetal 
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Neonatal thyroid screening results are 












Overt maternal thyroid dysfunction during gestation is associated with poor 
neonatal thyroid function. However, research on the relationship between 
suboptimal maternal thyroid function (assessed at 3 trimesters) and neonatal 
thyroid screening outcome is scarce.   
 
Objective 
To study the relationship between maternal thyroid function at each pregnancy 
trimester and neonatal screening results. 
 
Design 
Prospective follow-up study during three trimesters of gestation in 886 Dutch 
Caucasian healthy pregnant women followed from 12 weeks gestation until term 
delivery (≥ 37 weeks) and their neonates. 
 
Main outcome measure 
The relation between neonatal data from the Congenital Hypothyroidism (CH) 
screening and maternal thyroid determinants (TSH, FT4 and TPO-Ab) assessed 
at 12, 24 and 36 weeks gestation.  
 
Results 
Boys have lower screening TT4 levels and their mothers have higher TSH levels 
at 24 and 36 weeks gestation. Lower screening TT4 levels are independently 
related to high-normal maternal TSH levels (> 97.5th percentile, as defined in 
810 women without TPO-Ab at 12 weeks) at one or more times during 
pregnancy (OR: 2.15, 95% CI: 1.11 - 3.99) and lower gestational age (OR: 0.81, 
95% CI: 0.70 - 0.94). 
 
Conclusions 
Maternal thyroid function during gestation is related to neonatal TT4 at 
screening. Future research should also link TSH-based neonatal screening 
results to maternal thyroid function, assessed throughout pregnancy. The finding 
of both lower neonatal TT4 levels in boys and higher TSH levels in mothers 
carrying boys is worthy of further investigation, as both observations may be 
meaningfully related.  
 





The foetus is totally dependent on maternal thyroid hormone supply during the 
first half of gestation. This dependency decreases during the second half of 
gestation when the ongoing maturation of the foetal hypothalamus-pituitary-
thyroid axis (HPT axis) results in increased foetal T4 production.1,2 
Evidence on whether poor neonatal thyroid screening results are dependent on 
(sub)clinical maternal thyroid dysfunction during gestation is limited. In iodine 
deficient areas, some studies found higher mean cord TSH levels compared to 
mean maternal TSH levels during different trimesters of gestation and at 
delivery.3,4,5 Another study revealed a positive correlation between maternal 
FT4 and cord rT3 and between maternal rT3 and cord T3.6 A recent study 
failed to demonstrate a relation between maternal thyroid function and neonatal 
screening results.7 Conclusions based on these studies, however, cannot be 
definitive as they share a similar shortcoming: assessments of maternal thyroid 
function were done at a single, variable time point (12 - 24 weeks gestation), 
while the effect of maternal thyroid function on foetal thyroid development 
might be trimester-specific.8,9 
This study reports on the neonatal thyroid screening outcome of a large group 
of healthy term born (≥ 37 weeks) neonates (n = 886), whose healthy mothers 
were followed at each trimester until delivery. Primary outcome was the 
relation between maternal thyroid function at each trimester and neonatal total 
T4 (TT4) screening results, after adjustment for other determinants of 





Over a 2-year period, 1190 out of 1507 Dutch Caucasian pregnant women living 
in the Eindhoven city area consented to participate in a follow-up study at their 
first antenatal control visit at 12 weeks gestation. For various reasons (e.g., 
thyroid medication, overt hyperthyroidism/hypothyroidism at screening, severe 
congenital malformations, hormone induced pregnancy, diabetes-I, missing data) 
56 women were excluded. The remaining 1134 women were followed 
throughout pregnancy. Seventy-two of them delivered prior to 37 weeks 
gestation. Of the remaining 1062 women, 886 (83%) mothers gave written 
consent to access Congenital Hypothyroidism (CH) screening data. The Medical 




Free thyroxine (FT4), thyrotropin (TSH) and auto-antibodies to thyroid 
peroxidase (TPO-Ab) were assessed at 12, 24 and 36 weeks gestation. TSH was 





assay (IMMULITE Third generation TSH, Diagnostic Products Corporation, Los 
Angeles, USA). FT4 concentration was measured by means of a solid-phase 
immunometric assay (IMMULITE Free T4). The IMMULITE TPO-Ab kit was 
used for the determination of antibodies against thyroid peroxidase (TPO). 
Women with TPO-Ab concentrations > 35 kU/l at 12 weeks gestation were 
regarded as antibody positive. In The Netherlands, neonatal CH screening is 
performed by primarily assessing TT4 in heel puncture blood samples collected 
on filter paper. The TT4 concentration was compared with the mean TT4 of all 
neonates assessed that day in the screening laboratory. Babies with a TT4 ≥ 0.8 
SD below the daily mean receive a TSH assessment: by definition this is around 
20% of all neonates.10  
 
Statistical analysis 
To evaluate whether neonatal TT4 was related to maternal and neonatal 
parameters, we performed Pearson correlations (two-tailed), t-tests (two-
tailed) and analysis of variance (ANOVA). Subsequently, different cutoffs for 
maternal TSH and FT4 were calculated, and chi-squares (χ2) were used to test 
associations with neonatal TT4. Determinants of low neonatal screening TT4 
(defined as ≥ 0.8 SD below the mean of the total study sample) were analyzed 
using multiple logistic regression analysis (OR, 95% CI).  
 
Results 
Mothers carrying male foetuses (table 1) had significantly higher mean TSH 
levels at 24 and 36 weeks gestation compared to mothers carrying girls, while 
mean FT4 did not differ. The number of women with elevated TPO-Ab titers 
did not differ as a function of foetal sex. Heel punctures for CH screening were 
performed at a mean age of 5.2 days (SD = 0.56). As shown in Table 1, mean 
overall neonatal TT4 at screening was 179 nmol/l (SD = 38 nmol/l). Boys had 
significantly lower mean TT4 levels compared to girls (t = 3.1, p = 0.002). 
Neonates born at 37 - 38 weeks gestation had significantly lower mean TT4 
levels compared to those who were born ≥ 38 weeks gestation (F = 5.6, p < 
0.001). This was also true for boys born at 37 - 38 weeks versus boys born ≥ 38 
weeks gestation (F = 3.8, p = 0.002), while in girls this difference was only 
significant at the 90% level (F = 2.0, p = 0.07).  
In the 810 women who were TPO-Ab negative at 12 weeks gestation, TSH and 
FT4 were defined as low and high using the lowest 2.5th and upper 97.5th 
percentiles as cutoffs (i.e., to denote the 5% extremes of the general population; 
Table 2). Mean TT4 was the lowest in the TSH > 97.5th percentile at 12 and 36 
weeks gestation. Moreover, the percentage of neonates with low TT4 was the 
highest in the group with a TSH > 97.5th percentile, especially at 12 weeks (p = 
0.03), and to a lesser degree at 36 weeks (p = 0.08). No differences in neonatal 
TT4 level among the maternal FT4 percentile groups were found for any of the 
three trimesters (Table 2).  





Table 1. Maternal thyroid function during gestation and heel TT4 values assessed 
between 3 - 5th postpartum day in 886 at term born neonates (> 37 weeks). 
  Total n = 886 
Mn (SD) 
Boys n = 464 
Mn (SD) 
Girls n = 422 
Mn (SD) 
t p 
Maternal thyroid function     
TSH 1.23 (0.79) 1.27 (0.81) 1.19 (0.77) 1.5 0.13 12 weeks 
gestation 
FT4 16.1 (2.51) 16.2 (2.50) 16.1 (2.49)  0.5 0.58 
TSH 1.35 (0.67) 1.40 (0.74) 1.29 (1.59) 2.5 0.01 24 weeks 
gestation 
FT4 13.9 (2.07) 14.0 (2.13) 13.8 (1.92) 1.6 0.14 
TSH 1.51 (0.78) 1.56 (0.79) 1.45 (0.69) 2.2 0.03 36 weeks 
gestation 
FT4 13.3 (2.16) 13.4 (2.11) 13.2 (2.25) 0.6 0.5 
Neonatal Heel results     
        TT4 overall 179 (38) 176 (36) 184 (39) 3.1 0.002 
    37 weeks n = 52, 164 (39) n = 35,    160 (38) n = 17,  172 (39)   
    38 weeks n = 122, 170 (37) n = 70,    167 (37) n = 52,  174 (36)   
    39 weeks n = 226, 177 (40) n = 115,  173 (39) n = 111, 181 (41)   
    40 weeks n = 260, 184 (36) n = 125,  182 (33) n = 135, 186 (39)   
    41 weeks n = 174, 186 (35) n = 91,    183 (34) n = 83,  188 (36)   
    > 41weeks n = 52 188 (40) n = 28,    180 (37) n = 24,   197 (42)   
  
Subsequently, women with a TSH > 97.5th percentile at least once during 
gestation were designated as the high-normal TSH group (n = 62 [7%] of total 
sample) of whom 21 (34%) had elevated TPO-Ab. Multiple logistic regression 
showed that high-normal maternal TSH (> 97.5th percentile) during gestation 
(OR: 2.15, 95% CI: 1.11 - 3.99) and gestational age ≥ 37 weeks  (OR: 0.81, 95% 
CI: 0.70 - 0.94) were independently related to low heel TT4 (≥ 0.8 SD below 
the mean = 149 nmol/l) while alcohol use and smoking during gestation, 







Table 2. Mean screening TT4 (SD) and numbers (%) of neonates with low screening TT4  
(≥ 0.8 SD below the mean: < 149 nmol/l) according to maternal TSH cutoffs at three 
different trimesters, assessed in women without TPO-Ab at 12 weeks gestation. 
 Mean TT4 (SD) 
 
Total n = 886 
Low TT4 
(<149 nmol/l) 
Total n = 189 
12 weeks   
TSH < 2.5th percentile, <  0.16 mIU/l  + 178 (29) 3 / 26 = 11% 
TSH between 2.5th - 97.5th percentile, 0.16 - 2.9 mIU/l  181 (37) 175 / 832 = 21%   
TSH > 97.5th percentile, > 2.9 mIU/l  167 (39) 11 / 28  = 39%  *     
24 weeks   
TSH < 2.5th percentile, < 0.41 mIU/l  171 (40) 7 / 26  = 27%       
TSH between 2.5th - 97.5th percentile, 0.41 - 2.77 mIU/l  172 (37) 173 / 830  = 21% 
TSH > 97.5th percentile, > 2.77 mIU/l  170 (34) 9 / 30 = 30% 
36 weeks   
TSH < 2.5th percentile, < 0.42 mIU/l  173 (35) 6 / 38 = 16%        
TSH between 2.5th - 97.5th percentile, 0.42 - 3.10 mIU/l  180 (38) 174 / 825  = 21% 
TSH > 97.5th percentile, > 3.10 mIU/l  165 (38) 9 / 23 = 39%   ** 
+: TSH percentiles assessed in 810 women without TPO-Ab at 12 weeks gestation;  
* = χ2  (2): 6.9, p = 0.03; ** = χ2  (2): 5.1, p = 0.08 
 
Discussion 
Our results contrast with those of a recent study7 in which, however, maternal 
thyroid function was only assessed once in the first half of pregnancy (< 22 
weeks) and high TSH was defined as > 2.5 mIU/l. Because a possible impact of 
sub-optimal maternal thyroid function on foetal thyroid function could be 
trimester-specific, the current study opted for maternal thyroid function tests in 
each trimester.8,9 Moreover, we used a different cutoff for high maternal TSH by 
defining trimester-specific upper TSH levels as > 97.5th percentile in TPO-Ab 
negative women (2.9 mIU/l, 2.77 mIU/l and 3.1 mIU/l respectively).  
How can the link between high-normal maternal TSH during gestation and low 
neonatal TT4 levels at screening be explained?  During the first half of gestation, 
foetal thyroid function is totally dependent on maternal T4 supply. After the 
onset of foetal thyroid function, maternal T4 transfer continues until term and 
represents an important proportion of thyroid hormones available to the 
foetus1,2, although most of the maternal T4 supply is inactivated by deiodinase 3 
(D3) into rT3. Inadequate supply of maternal T4 during gestation (reflected by 
high maternal TSH) may result in lower foetal T4 and T3 levels. In the current 
study, women in the high-normal TSH group had lower, albeit non-significant, 
FT4 levels at 12 and 24 weeks gestation. High-normal maternal TSH reflecting 
lower maternal FT4 levels at early gestation may be indicative of reduced FT4 
availability for the foetus throughout pregnancy, which in turn may result in 
lower neonatal screening TT4 levels. Moreover, one third (37%) of the women 
with high-normal TSH showed elevated TPO-Ab concentrations, reflecting 
thyroid auto-immunity. These women are known to be at risk for impaired 




maternal-foetal transfer of FT4.11 No differences in neonatal TT4 level among 
the maternal FT4 percentile groups were found for any of the three trimesters. 
This may be due to the greater sensitivity of TSH to detect small changes in the 
set point of the HPT axis compared with FT4.12 Besides, it has been reported 
that pregnancy FT4 assessments are less reliable than non-pregnancy 
assessments.13 Alternatively, it could be that a sub-sample of pregnant women in 
our study may have had increased placental deiodinase activity, which would 
explain their increased TSH levels in order to preserve their euthyroid state. 
Increased placental deiodinase, as such, would then be the likely cause of 
decreased foetal T4 availability, and hence lower screening neonatal TT4 levels.  
Our finding that maternal TSH at 24 weeks was unrelated to low neonatal TT4 
is difficult to explain. One may speculate that this decreased maternal T4 
dependency mirrors the mid-gestation rise in foetal T4 production. It should be 
realized, however, that foetal T4 availability is dependent on a complex system 
of currently (largely) unknown maternal, placental and foetal regulatory 
components.  
Possible determinants related to normal TT4 (and TSH) in healthy term babies 
such as gestational age and foetal sex (boys) have been described earlier. 
7,14,15,16,17,18 To our knowledge, this is the first report describing higher TSH 
levels in pregnant women carrying a male foetus. An explanation for this finding 
is lacking, but one may speculate that male foetuses have a more active 
deiodinase activity than female foetuses, given consistent reports that boys have 
lower neonatal TT4 (and higher cord TSH) compared to girls.7,16,18 However, in 
the current study, amniotic fluid data or newborn T3 values to support this 
hypothesis were not available. Moreover, the question whether this finding is 
clinical relevant, remains unresolved. It would be interesting to study whether 
neonatal male TT4 levels are associated with any of the neurodevelopmental 
problems known to preferentially affect boys. 
Several limitations of the study need to be mentioned. First, iodine excretion 
data in mothers and neonates were not collected. It might be argued that 
increased maternal TSH and lower neonatal screening TT4 reflect the same 
underlying mechanism: sub-optimal iodine intake. Although all participants lived 
in iodine sufficient areas, it is questioned whether adequate iodine intake 
outside pregnancy also guarantees sufficient iodine intake to meet the demands 
of pregnancy.19 Second, cutoffs to define elevated TSH (and FT4) cannot be 
compared with trimester-specific reference ranges of TSH, because they do not 
exist. Using the 5% extremes of the group in TPO-Ab negative women, as is 
done in the general population, appears to be the most valid approach available. 
Third, the absence of thyroid cord blood data did not allow us to examine 
whether the obtained association between high maternal TSH and low neonatal 
screening TT4 was already present in utero. On the other hand, a major 
strength of the study is the rather strict time frame of thyroid hormone 





Future research should consider linking TSH-based neonatal screening results 
(besides TT4) to maternal thyroid function, assessed at fixed time points for 
each trimester of pregnancy. The finding of both lower neonatal TT4 levels in 
boys and higher TSH levels in mothers carrying boys is worthy of further 
investigation, as both observations may be meaningfully related.  
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Minder keizersneden wegens stuitligging 
dankzij geprotocolleerde uitwendige 









Identificatie van factoren die de kans op een succesvolle uitwendige versie van 
kinderen in stuitligging beïnvloeden, en evaluatie van het effect dat poliklinische, 






In 2003 werd een protocol voor uitwendige versie ontwikkeld op de polikliniek 
Verloskunde van het Catharina-ziekenhuis te Eindhoven; dit werd getoetst in 
een ‘versiespreekuur’. Van alle zwangeren bij wie in de periode januari 2004-juni 
2006 tijdens dit spreekuur een poging tot uitwendige versie was uitgevoerd, 
werden obstetrische kenmerken en de partus geanalyseerd. Van de versies 
werd 85% uitgevoerd door dezelfde 2 personen (1 verloskundige en 1 
gynaecoloog), volgens het protocol. 
 
Resultaten 
Uitwendige versie bleek succesvol bij 96 van de 209 zwangeren (46%). Bij 1 
zwangere moest na de versie een spoedsectio worden verricht wegens een 
partiële abruptio placentae. Nullipariteit, onvolkomen stuitligging en een laag 
geboortegewicht van de baby hingen in deze studie samen met een kleinere kans 
op een succesvolle versie. In de groep waarin de versie succesvol was, was het 
percentage geboorten via sectio caesarea aanmerkelijk lager (9 versus 83%; OR: 
0,21; 95%-BI: 0,09-0,51). 
 
Conclusie 
Uitwendige versie die volgens een standaardprotocol werd uitgevoerd door een 
vast team, bestaande uit een verloskundige en een gynaecoloog, bleek effectief 
te zijn: door uitwendige versie nam het aantal à terme stuitliggingen af en 
daarmee het percentage sectio’s. Dit kan leiden tot een aanzienlijke 
gezondheidswinst voor de moeder en een belangrijke kostenbesparing voor de 
gezondheidszorg in Nederland. 
 
 




Bij 3-5% van de vrouwen met een à terme zwangerschap (≥ 37 weken) heeft de 
foetus een stuitligging. Wat het optimale obstetrische beleid is bij stuitligging, is 
tot op heden onderwerp van heftige discussie. In 2000 suggereerden de 
uitkomsten van een groot multicentrisch onderzoek, de ‘Term breech trial’, dat 
een partus langs vaginale weg bij stuitligging gepaard ging met een toegenomen 
neonatale morbiditeit en sterfte.1 Als gevolg hiervan nam in Nederland het 
aantal sectio’s wegens stuitligging bij een à terme zwangerschap drastisch toe: 
van 50% in 2000 tot 80% in 2006.2,3 Bij nadere, kritische beschouwing van deze 
multicentrische studie, en ook bij vervolgonderzoek van de onderzoekers zelf, 
werd echter de validiteit van de bevindingen achteraf ernstig in twijfel 
getrokken.4-6 De trend naar meer sectio’s wegens stuitligging was toen al 
begonnen.  
De nadelen van sectio’s, namelijk toegenomen maternale morbiditeit en sterfte 
en forse toename van obstetrische complicaties bij toekomstige 
zwangerschappen, zijn genoegzaam bekend.7,8 
In de obstetrie bestaat er al vele decennia een relatief veilige methode om een à	  
terme stuitligging te voorkomen: de uitwendige versie. Uit recente 
internationale literatuur blijkt dat deze methode het aantal sectio’s aanzienlijk 
doet afnemen.9-11 Wat de determinanten van een succesvolle versie zijn, weet 
men nog maar ten dele.12-15 De laatste Nederlandse cijfers over uitwendige 
versies dateren van 1990.16 In het betreffende artikel werd het nut van 
uitwendige versie niet groot geacht omdat in die tijd een vaginale bevalling bij 
stuitligging de voorkeur had. Inmiddels echter is het aantal keizersneden bij 
stuitligging spectaculair toegenomen. Het is dus gerechtvaardigd om veel 
aandacht te besteden aan uitwendige versie en aan een zo efficiënt mogelijke 
uitvoering hiervan. 
In de huidige studie beschrijven wij de resultaten van een apart opgezet 
poliklinisch ‘versiespreekuur’. Tijdens dit spreekuur verrichtte een klein team 
van speciaal getrainde obstetrici (2 gynaecologen en 1 tweedelijnsverloskundige) 
een versie volgens een standaardprotocol. De resultaten van ruim 200 versies in 
de periode 2004-2006 werden geanalyseerd. 
Aan de hand van deze bevindingen wordt nader ingegaan op de recent in 
Nederland opgelaaide discussie over de vraag waar een versie het beste kan 




Patiënten en methoden 
 
Versieprotocol. Gedurende een periode van 1 jaar (2003) werd op de 
polikliniek Verloskunde van het Catharina-ziekenhuis te Eindhoven een 




Hierbij was het streven de versies zoveel mogelijk te laten uitvoeren door een 
klein aantal speciaal hierin getrainde medewerkers: 1 verloskundige en 2 
gynaecologen. Alle medewerkers dienden zich aan het versieprotocol te houden 
om een effectieve evaluatie van het beleid mogelijk te maken. 
In de onderzoeksperiode werd 85% van de versies uitgevoerd door dezelfde 2 
personen (1 verloskundige en 1 gynaecoloog), volgens het protocol. Hierbij 
duwde een van de twee de stuit uit het bekken terwijl het foetale hoofd door 
de ander richting bekkeningang werd geduwd. Tijdens de kering controleerde 
een derde medewerker echoscopisch de harttonen en de ligging van het kind. 
Zo nodig werd een weeënremmer toegediend na klinische beoordeling van de 
tonus van de uterus vóór versie. 
 
Tabel 1. Protocol voor de uitwendige versie van een foetus in stuitligging, ontwikkeld op 
de polikliniek Verloskunde van het Catharina-ziekenhuis te Eindhoven 
1. anamnese afnemen, informeren van de patiënte over de procedure en uitsluiten van contra-
indicaties 
2. echoscopisch onderzoek om de ligging van de foetus, de ligging van de placenta en de 
vruchtwaterindex te bepalen 
3. cardiotocografie om foetaal welzijn te bevestigen  
4. optioneel: toediening weeënremmer (atosiban 6,75 mg i.v.) 
5. uitwendige kering 
6. echoscopie na de versie om de foetale ligging te bevestigen 
7. cardiotocografie na de versie 
8. toediening van rhesus(D)immunoglobuline als de rhesusbloedgroep van de moeder negatief 
is 
 
Patiënten. Gedurende de periode 1 januari 2004-30 juni 2006 kregen alle 
zwangeren met een foetus in stuitligging (vastgesteld door een 
eerstelijnsverloskundige of een gynaecoloog bij een zwangerschapsduur van 32-
34 weken) uitleg over de mogelijkheid van een uitwendige versie als onderdeel 
van ‘good clinical practice’. Na instemming van de zwangere (n = 280) vond 
verwijzing plaats naar het versiespreekuur bij een zwangerschapsduur van 
ongeveer 35-36 weken. De poging tot versie werd onmiddellijk na de verwijzing 
uitgevoerd. 
Bij echoscopische controle volgens het protocol bleek dat bij 62 vrouwen de 
foetus een hoofdligging had. Er waren 9 vrouwen met een contra-indicatie voor 
versie: dwarsligging van de foetus (6), oligohydramnion (1) of een afwijkend 
foetaal hartfrequentiepatroon (2). Deze vrouwen (71 in totaal) werden 
geëxcludeerd; de data-analyse betreft dus 209 casussen. 
De uitkomstmaten waren het percentage succesvolle versies en het percentage 
vaginale bevallingen na een geslaagde versie. Een versiepoging werd als succesvol 
gedefinieerd als direct na de poging echoscopisch een hoofdligging werd 
aangetoond. Verschillende determinanten waarvan uit de literatuur bekend was 
dat ze konden samenhangen met de uitkomst van uitwendige versie werden 




geregistreerd, zoals de zwangerschapsduur bij versie, de pariteit, het type 
stuitligging, de ligging van de placenta, en het neonatale geboortegewicht. 
 
Statistische analyse. De data werden geanalyseerd met behulp van het 
Statistical Package for the Social Sciences (SPSS), versie 14.0 (SPSS Inc., Chicago, 
VS). Verschillen in prevalenties van categoriale variabelen werden onderzocht 
met behulp van een χ2-toets. Verschillen in gemiddelde waarden van continue 
variabelen (zwangerschapsduur, gewicht, leeftijd) werden onderzocht met 
behulp van een tweezijdige t-toets. De samenhang tussen de afhankelijke 
variabele (geslaagde versie) en een set van onafhankelijke variabelen werd 
getoetst met een logistische-regressieanalyse. 
 
Resultaten 
In tabel 2 zijn de patiëntkenmerken en het succespercentage na uitwendige 
versie weergegeven, opgesplitst naar pariteit. 
Uitwendige versie bleek succesvol bij 96 van de 209 zwangeren (46%). Bij 
multiparae was de versie statistisch significant vaker succesvol dan bij nulliparae 
(oddsratio (OR): 1,91; 95%-BI: 1,29-2,84). Tabel 2 laat verder zien dat er een 
statistisch significant verschil was tussen nulliparae (n = 121) en multiparae (n = 
88) in de zwangerschapsduur bij versie. 
 
Tabel 2. Obstetrische kenmerken van zwangeren vóór, tijdens en na geprotocolleerde 
uitwendige versie van een foetus in stuitligging, in een onderzoek naar de resultaten van 
een poliklinisch ‘versiespreekuur’ 
Obstetrische kenmerken Totaal 
(n = 209) 
Nulliparae 
(n = 121) 
Multiparae 
(n = 88) 
vóór versie 
gemiddelde leeftijd (SD) 31,2 (4,4) 30,7 (4,8) 31,8 (3,7) 
gemiddelde zwangerschapsduur in weken (SD) 36,2 (1,1) 36,0 (0,9)  36,4 (1,3)* 
obstetrische anamnese (huidige zwangerschap); n (%) 
     diabetes gravidarum 1 (0,5) 1 (0,8) - 
     IUGR 1 (0,5) 1 (0,8) - 
ligging placenta; n (%) 
     anterieur 76 (36)  39 (32) 37 (42) 
      posterieur 84 (40)  54 (45) 30 (34) 
      lateraal 15 (7)  9 (7) 6 (7) 
      fundaal 8 (4)  5 (4) 3 (3) 
     overig 26 (12)  14 (12) 12 (14) 
type stuitligging; n (%) 
     volkomen 51 (24)  29 (24) 22 (25) 
     onvolkomen 135 (65)  80 (66) 55 (62) 
     overig 23 (11)  12 (10) 11 (13) 
complicaties tijdens versie; n (%) 
      abnormaal cardiotocogram 3 (1,4)  2 (1,7) 1 (1) 
      PPROM 1 (0,5)  1 (0,8)  - 
      vaginaal bloedverlies 1 (0,5)  1 (0,8)  - 
      partiële abruptio placentae die spoedsectio nodig 
maakte 
1 (0,5)  1 (0,8)  - 
hoofdligging na versie; n (%) 96 (46) 44 (36) 52 (59)† 
IUGR = intra-uteriene groeiretardatie; PPROM = ‘preterm premature rupture of membranes’. 
*Uitkomst statistisch significant verschillend van die bij nulliparae; tweezijdige t-toets, p < 0,05. 




Er was geen noemenswaardig verschil tussen nulliparae en multiparae wat 
betreft andere obstetrische factoren die een uitwendige versie kunnen 
beïnvloeden (zie tabel 2). Bij 1 nullipara (0,5% van het totale aantal zwangeren) 
moest na de versie een spoedsectio worden verricht wegens een partiële 
abruptio placentae; het kind werd in goede conditie geboren. 
 
Tabel 3. Resultaten van een logistische-regressieanalyse waarin de invloed van 
obstetrische kenmerken op het succes van geprotocolleerde uitwendige versie van een 
foetus in stuitligging is onderzocht 
obstetrische kenmerken univariate analyse multivariate analyse 
 OR 95%-BI OR 95%-BI 
leeftijd zwangere 1,05  0,98-1,12 1,03 0,96-1,10 
zwangerschapsduur bij versie 1,23  0,96-1,58 1,14 0,87-1,49 
nullipariteit 0,40*  0,23-0,71 0,42† 0,23-0,78 
onvolkomen stuitligging 0,41*  0,23-0,74 0,48† 0,25-0,89 
laag placentagewicht‡ 0,33*  0,12-0,93 0,61 0,31-1,23 
anterieure ligging placenta 0,62   0,34-1,10 0,59 0,31-1,11 
laag geboortegewicht baby§ 0,35*  0,12-0,98 0,33† 0,15-0,72 
*Significant minder succesvolle versies als dit kenmerk aanwezig was (univariate logistische- regressieanalyse). 
†Significant minder succesvolle versies als dit kenmerk aanwezig was (multivariate logistische-regressieanalyse). 
‡Placentagewicht < P10 (< 486 g). 
§Geboortegewicht < P10 (< 2637 g). 
     
Tabel 3 geeft de resultaten van een univariate logistische-regressieanalyse weer, 
waarbij de uitkomst van de versie (succesvol/niet succesvol) de afhankelijke  
variabele was. De leeftijd werd gerekend in jaren, de zwangerschapsduur in 
weken. Nullipariteit is hierbij vergeleken met multipariteit (die laatste term geeft 
aan dat een vrouw 1 of meerdere partussen heeft doorgemaakt); onvolkomen 
stuitligging is vergeleken met volkomen stuitligging. De volgende variabelen 
bleken een statistisch significante invloed te hebben op het succes van de poging 
tot versie: nullipariteit, onvolkomen stuitligging, laag placentagewicht (< P10) en 
laag geboortegewicht van het kind (< P10). 
Tabel 3 geeft ook de resultaten van een multivariate logistische-regressieanalyse 
weer, waarbij de uitkomst van de versie opnieuw de afhankelijke variabele was. 
Bij nullipariteit, onvolkomen stuitligging en laag geboortegewicht bleek in deze 
cohort de kans op een succesvolle versie kleiner te zijn. 
In tabel 4 zijn de obstetrische kenmerken van de partus weergegeven. Het 
gemiddelde geboortegewicht van de baby’s was bij multiparae hoger dan bij 
nulliparae. Voor de hele groep (n = 209) was het aantal sectio’s na een 
succesvolle versie statistisch significant kleiner dan bij een persisterende 
stuitligging: 9 versus 83% (OR: 0,21; 95%-BI: 0,09-0,51). 
Dit gold ook voor nulli- en multiparae afzonderlijk. 





Tabel 4. Kenmerken van de partus bij zwangeren die een geprotocolleerde uitwendige 
versie van een foetus in stuitligging hadden ondergaan 
Kenmerken van de partus Totaal 
(n = 209) 
Nulliparae 
(n = 121) 
Multiparae 
(n = 88) 
p 
gemiddelde zwangerschapsduur in weken (SD) 39,2 (2,5)  39,0 (3,1) 39,6 (1,3)  
gemiddeld geboortegewicht in g (SD) 3 288 (504)  3 213 (510) 3 389 (481)* 0,005 
     
wijze van bevallen (totaal); n (%)     
vaginaal in hoofdligging 90 (43)  36 (30) 54 (61)† < 0,001 
vaginaal in stuitligging 16 (8)  7 (6) 9 (10)  
primaire sectio bij stuitligging 81 (39)  59 (49) 22 (25)† 0,001 
secundaire sectio bij hoofdligging 9 (4)  8 (7) 1 (1)  
secundaire sectio bij stuitligging 13 (6)  11 (9) 2 (2)† 0,04 
     
na succesvolle versie; n (%) 96  44 52  
vaginale partus 87 (91)  36 (82) 51 (98)† 0,006 
secundaire sectio caesarea 9 (9)  8 (18) 1 (2)† 0,006 
     
na niet succesvolle versie; n (%) 113  77 36  
vaginale partus hoofd‡ 3 (3)  0 3 (8)  
vaginale partus stuit 16 (14)  7 (9) 9 (25)† 0,02 
primaire sectio caesarea 81 (71)  59 (77) 22 (61)  
secundaire sectio caesarea 13 (12)  11 (14) 2 (6)  
*Uitkomst statistisch significant verschillend van die bij nulliparae; tweezijdige t-toets. 
†Uitkomst statistisch significant verschillend van die bij nulliparae; χ2 -toets. 
‡Na een niet succesvolle uitwendige versie hadden 3 multiparae een spontane versie. 
 
Beschouwing 
Het opzetten van een spreekuur voor uitwendige versie, waarbij een vast team 
van specialisten (verloskundigen en gynaecologen) volgens een 
standaardprotocol werkt, lijkt erg efficiënt. Uitwendige versie bleek succesvol bij 
96 van de 209 zwangeren (46%). 
In de literatuur wordt voor uitwendige versie een succespercentage van 35-86 
beschreven.12 In een enquête onder de Nederlandse gynaecologen bleek dat er 
in slechts 19% van de maatschappen een formele registratie plaatsvond van het 
aantal versiepogingen en de slagingspercentages. Het slagingspercentage van de 
niet-geregistreerde pogingen werd ruwweg op 36 geschat; het 
slagingspercentage van de wél geregistreerde versiepogingen was hoger: 44.20 
Ons slagingspercentage van 46 komt hiermee overeen. In ons onderzoek blijken 
nullipariteit, onvolkomen stuitligging en laag geboortegewicht de belangrijkste 
factoren te zijn die de succeskans bij een versiepoging verkleinen, conform de 
literatuur.12,21 
Uit een cochrane-review blijkt dat versie een statistisch significante en klinisch 
relevante afname bewerkstelligt van het aantal sectio’s (OR: 0,55; 95%-BI: 0,33-
0,91).22 Ook in onze studie nam het aantal sectio’s fors af: van 83% bij 
persisterende stuitligging tot 9% na succesvolle versie. Uitwendige versie blijkt - 
in een klinische setting - ook een veilige methode te zijn. Er werden 




cardiotocogram (CTG) geconstateerd, maar er trad bij slechts 1 zwangere 
(0,5%) een ernstige complicatie op, namelijk een partiële abruptio placentae 
waarvoor een spoedsectio binnen een half uur noodzakelijk was. Dit lage 
percentage complicaties komt overeen met gegevens uit de literatuur.23-25 
 
Versie in de eerste lijn of in de kliniek. 
Recent is er in Nederland discussie ontstaan over de plaats waar een uitwendige 
versie kan plaatsvinden, nu de Koninklijke Nederlandse Organisatie van 
Verloskundigen met de zorgverzekeraars afspraken heeft gemaakt om versies 
buiten de kliniek uit te laten voeren onder verantwoordelijkheid van de 
eerstelijnsverloskundigen 
(www.ziekenhuis.nl/index.php?cat=nieuws&nieuws=item&id=5242&nieuwstype=pat).17-19 Deze 
aanpak strookt niet met Amerikaanse en Engelse richtlijnen, noch met de 
richtlijn van de Nederlandse Vereniging voor Obstetrie en Gynaecologie 
(NVOG); in die richtlijnen wordt gesteld dat continue registratie van de foetale 
hartfrequentie (CTG) bij versie een absolute voorwaarde is en dat een klinische 
setting strikt noodzakelijk is omdat daar - indien nodig - snel een spoedsectio 
kan worden uitgevoerd.12,26,27 
Bovendien wordt het succespercentage mogelijk beperkt door een aantal 
mechanische factoren. In sommige gevallen biedt het toedienen van een 
weeënremmer hierbij uitkomst, maar dit valt niet onder de bevoegdheid van de 
eerstelijnsverloskundige.28 
Naar onze mening is het routinematig uitvoeren van uitwendige versies een 
eerste vereiste voor goede expertise. In een verloskundige normpraktijk doen 
zich per jaar 3-5 stuitliggingen voor.29 Op basis van dit kleine aantal kan men 
geen goede expertise opbouwen; dat geldt overigens eveneens voor 
verloskundigen in de tweede lijn. Een gynaecoloog die incidenteel een versie 
uitvoert, zal ook niet genoeg handigheid opbouwen. Daarom pleiten wij voor 
het opzetten van een polikliniek voor uitwendige versie met een vast team van 
getrainde obstetrici (verloskundigen of gynaecologen). 
 
Relevantie voor de gezondheidszorg. 
De implementatie van een versiespreekuur leidt niet alleen tot afname van 
maternale morbiditeit, maar ook tot een aanzienlijke kostenbesparing voor de 
gezondheidszorg.30-32 In een artikel in Medisch Contact uit 2006 zijn de kosten in 
Nederland van een sectio caesarea vergeleken met die van een instrumentele 
partus. De sectio kostte € 5594,11 euro en de partus € 993,86 (een verschil van 
€ 4600,00).3 
Op de huidige studie zou de volgende kostenanalyse van toepassing kunnen zijn. 
Van de groep vrouwen bij wie de uitwendige versie niet succesvol was, kreeg 
71% een primaire sectio. Laten we aannemen dat dit percentage hetzelfde zou 
zijn geweest bij de succesvol behandelde groep (n = 96) als er geen versiepoging 
had plaatsgevonden. Dan waren in deze groep zonder versiepoging ongeveer 68 




primaire sectio’s te verwachten geweest. Dit suggereert dat uitwendige versie in 
een groep van 209 zwangeren met een kind in stuitligging een kostenbesparing 
oplevert van ruim € 300.000 (68 ×  € 4600). Op een landelijke schaal van 8000 
stuitliggingen per jaar zou dit een aanzienlijke besparing betekenen.  
Deze voorlopige schattingen rechtvaardigen nader onderzoek naar de 
kosteneffectiviteit van gestructureerde versie bij stuitligging. Een voorwaarde 
hierbij is dat zorgverleners uit de eerste en tweede lijn de zwangeren met een 
kind in stuitligging zoveel mogelijk verwijzen naar een versiespreekuur. 
 
Conclusie 
Uitwendige versie bij stuitligging is een goede methode om het aantal à terme 
stuitliggingen te verkleinen en het percentage sectio’s fors te laten dalen. De 
methode lijkt naast aanzienlijke gezondheidswinst voor de moeder een 
belangrijke kostenbesparing op te leveren. 
Elke zwangere met een kind in stuitligging moet, bij afwezigheid van contra-
indicaties, de mogelijkheid aangeboden krijgen van een versie door getrainde 
obstetrici (verloskundigen of gynaecologen) op een speciaal hiertoe ingericht 
poliklinisch versiespreekuur. 
Vanwege de noodzaak van foetale bewaking tijdens en na de versie, de 
mogelijkheid dat weeënremmers moeten worden toegediend en de, overigens 
zeer kleine, kans op een spoedsectio dient een versiepoging in de tweede lijn 
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Minder stuitbevallingen na invoering van 









Het effect onderzoeken van het doorvoeren van een aantal procesmatige 
beleidsregels, het zogenaamde procesprotocol, op het succespercentage van 






Gedurende een periode van 3 jaar (2004-2006) werd een standaardprotocol 
voor een spreekuur voor uitwendige versie ontwikkeld, getoetst en aangepast. 
Vervolgens werd na invoering van het procesprotocol het effect ervan op het 
percentage succesvolle versies prospectief gevolgd gedurende de periode januari 
2007-31 juli 2008. Een versie werd als succesvol gedefinieerd als direct na de 
poging echoscopisch een hoofdligging werd aangetoond. Secundaire uitkomst-




Het succespercentage van uitwendige versie was in de periode januari 2007-juli 
2008 significant hoger dan in de periode januari 2004-december 2006, namelijk 
61% (85/139 zwangeren) versus 47% (110/236; p = 0,006). De 
patiëntkarakteristieken waren in beide groepen gelijk, met uitzondering van 2 
subgroepen bij de termijn van versie. De stijging was vooral aantoonbaar bij 
nulliparae en multiparae met een onvolkomen stuitligging. Nullipariteit, 
onvolkomen stuitligging, placenta anterior en laag geboortegewicht van de baby 
waren gerelateerd aan een lagere succeskans bij versie. De termijn waarbij de 
versie plaatsvond bleek niet van invloed te zijn op het succespercentage. 
Na invoering van een procesprotocol steeg het aantal hoofdliggingen bij de 
partus en daalde het aantal primaire keizersneden voor stuitligging van 39 naar 
27% (p = 0,03). Het ‘number needed to treat’ om 1 sectio te voorkomen door 
middel van uitwendige versie volgens het procesprotocol, bedroeg 8. 
 
Conclusie 
Na invoering van een procesprotocol vond een aanzienlijke toename plaats van 
het succespercentage van uitwendige versie. Hierdoor daalde het aantal primaire 
sectio’s wegens stuitligging verder. Deze bevindingen pleiten voor het oprichten 
van verschillende, in uitwendige versie gespecialiseerde centra in Nederland. 
 




Uitwendige versie is de meest efficiënte methode om het aantal keizersneden bij 
stuitligging te verminderen. Het succespercentage van versie varieert in de 
internationale literatuur van 30-80%. Cijfers uit Nederlands onderzoek variëren 
echter van 25 - 41%.2-7 Deze verschillen kunnen deels verklaard worden door 
verschillen in etniciteit in de onderzoeksgroepen - bij negroïde vrouwen daalt 
het ongeboren kind in stuitligging later in het maternale bekken in - en 
selectiebias, waarbij te verwachten moeilijke casussen niet meegenomen werden 
in de analyse. Veelal ontbreekt deze laatste informatie in de literatuur. 
Vanaf 2004 werd in het Catharina-ziekenhuis te Eindhoven uitwendige versie 
volgens een standaardprotocol uitgevoerd door 2 obstetrici. Eén van hen was 
een lid uit een team van 3 ervaren versiespecialisten. De ander werd 
gerekruteerd uit een grote groep wisselende medewerkers, zoals arts-
assistenten en verloskundigen, die geen specifieke training hadden gehad in 
uitwendige versie of er ervaring in hadden opgebouwd. Recentelijk beschreven 
wij in dit tijdschrift de uitkomsten na invoering van het standaardprotocol: over 
de periode januari 2004 - juni 2006 bedroeg het succespercentage van de 
verrichte versies 46%.8 
Vanaf 2007 werkten wij dit standaardprotocol nader uit door het invoeren van 
een aantal procesmatige beleidsregels, hierna ‘procesprotocol’ genoemd. Deze 
wijzigingen waren samen te vatten onder de 4 R’s: regelmaat, routine, relaxatie 
en rust. ‘Regelmaat’ betekende: iedere week, op een vast tijdstip, een 
versiespreekuur. Met ‘routine’ bedoelden wij dat het team dat de versies 
uitvoerde bestond uit 4 ervaren obstetrici, namelijk 2 gynaecologen en 2 
verloskundigen. Iedere versie werd standaard door 2 leden uit dit team 
uitgevoerd. Om relaxatie van de uterus zoveel mogelijk te bevorderen, werd bij 
iedere versie altijd een weeënremmer gegeven. ‘Rust’ tenslotte, impliceerde dat 
deze vaste groep van ervaren medewerkers tijdens het versiespreekuur zoveel 
mogelijk van andere taken binnen de afdeling obstetrie werd vrijgesteld. De 
aanwezigheid van een doktersassistente bevorderde de accuraatheid van 
registratie van relevante data rondom een versie. 
Het huidige onderzoek betreft een eerste evaluatie van het nieuw gevoerde 
beleid vanaf 2007. Hierbij luidde de vraagstelling: is het mogelijk om na invoering 
van procesmatige beleidsregels het succespercentage van uitwendige versie te 
verhogen en het percentage sectio caesarea bij stuitligging verder te 
verminderen? 
 
Patiënten en methoden 
In de periode januari 2007 - juli 2008 kregen alle zwangeren, bij wie de foetus bij 
een zwangerschapsduur van 32-34 weken in stuitligging lag, vastgesteld door een 
eerstelijnsverloskundige uit de regio Eindhoven en omstreken of een 
gynaecoloog uit het Catharina-ziekenhuis, uitleg over de mogelijkheid van een 
uitwendige versie. Na instemming van de zwangere vond bij een 




versiespreekuur. De poging tot versie werd onmiddellijk na de verwijzing 
uitgevoerd. 
Verschillende determinanten, waarvan uit de literatuur bekend was dat ze 
mogelijk samenhangen met een succesvolle uitwendige versie, werden ten tijde 
van de versie geregistreerd, zoals de zwangerschapsduur bij versie, de pariteit, 
het type stuitligging en de ligging van de placenta. Bij de partus werd het 
geboortegewicht geregistreerd. De primaire uitkomstparameter van het 
onderzoek was het percentage succesvolle versies. Een versiepoging werd als 
succesvol gedefinieerd indien direct na de poging echoscopisch een hoofdligging 
werd aangetoond. Secundaire uitkomstmaat was een mogelijke verandering van 
het aantal primaire sectio’s bij stuitligging. Hierbij werd het percentage electieve 
sectio’s wegens stuitligging voor het doorvoeren van het procesprotocol 
berekend en vergeleken met het percentage electieve sectio’s na invoering. 
Vervolgens werd de reductie van het absolute risico op een electieve sectio 




De data werden geanalyseerd met behulp van de Statistical Package for the 
Social Sciences (SPSS), versie 16.0 (SPSS Inc., Chicago, VS). Verschillen in 
prevalenties van categorische variabelen werden onderzocht met behulp van 
een χ2-toets. Verschillen in gemiddelde waarden van continue variabelen 
(termijn, gewicht, leeftijd) werden onderzocht met behulp van een tweezijdige t-
toets. 
Bij de bestudering van de succespercentages van de verschillende jaren werd 
separaat gekeken naar de verdeling van de 2 belangrijkste voorspellers voor 
niet-succesvolle versie: primipariteit en onvolkomen stuitligging. Op deze manier 
kon worden nagegaan of een eventuele toename van het percentage geslaagde 
versies toe te schrijven was aan het voorkomen van relatief eenvoudigere 
casussen die zich in de periode van het vervolgonderzoek aandienden op het 
spreekuur. 
Tenslotte werd het logistische regressiemodel gebruikt (odds ratio (OR), 95%-
BI) om de samenhang tussen de afhankelijke variabele (al dan niet geslaagde 
versie) en de onafhankelijke variabele (procesprotocol) te beschrijven. Hiervoor 
werden alle versiepogingen over de periode 2004-2008 bij elkaar gevoegd, 
waarbij werd gedichotomiseerd in een versiepoging verricht volgens een 
procesprotocol of volgens een standaardprotocol (als referentie). Dit betekende 
in de praktijk: versiepoging voor of na 2006. De gecorrigeerde OR van 
succesvolle versie werden uitgerekend met het multiple logistische-
regressiemodel. Hierbij werd de lokalisatie van de placenta gedichotomiseerd in: 
anterior of niet anterior; het type stuit in: onvolkomen of overige types stuit; en 
het termijn bij versie in: voor of na 37 weken. Het geboortegewicht en het 
gewicht van de placenta werden gedichotomiseerd in: boven of onder het 10de 




percentiel van de totale groep. De leeftijd van de zwangere werd als een 
continue variabele ingevoerd. 
 
Resultaten 
In de periode januari 2007-juli 2008 werd aan alle patiënten, bij wie bij een 
termijn vanaf 32 weken een stuitligging werd vastgesteld, de mogelijkheid van 
een uitwendige versie voorgelegd. Na instemming van de zwangere (n = 208) 
vond verwijzing plaats naar het versiespreekuur vanaf een termijn van 35 weken. 
 
Tabel 1: Effect van het doorvoeren van een procesprotocol op het succes van 
uitwendige versie bij stuitligging. Karakteristieken van een patiëntengroep uit de periode 
2004-2006 (standaardprotocol, n=236) en een patiëntengroep uit 2007-2008 
(procesprotocol, n=139). 
 2004-2006 
n = 236 
2007-2008 
n = 139 
Totaal 
n = 375 
leeftijd in jaren, gemiddelde (SD) 31(4,4) 31(4,5) 31(4,4) 
pariteit, n (%)    
  nullipara 139(59)  86(62)  225(60) 
  multipara 97(41)  53(38)  150(40)  
type stuit, n (%)    
   volkomen 53(23)  36(26)  89(24)  
   onvolkomen 157(66)  93(67)  250(66)  
   half onvolkomen 26(11)  10(7)  36(10)  
termijn bij versie    
gemiddelde, in weken plus dagen 
( SD, in dagen) 
range in weken 
36+3(1,1) 
 
35 - 39 
36+4(1,2) 
 
35 - 39 
36+3(1,2) 
 
35 - 39 
< 36 weken, n(%)* 109(46)  46(33)  155(41)  
36-37 weken, n(%)** 70(30)  65(47)  135(36)  
37-38 weken, n(%) 34(14)  14(10)  48(13)  
>38 weken, n(%) 23(10)  14(10)  37(10)  
    
placentaligging bij versie, n(%)    
posterior 94(40)  62(45) 156(42)  
anterior 90(38)  55(40)  145(38)  
lateraal 52(22)  22(15)  74(20)  
    
obstetrische kenmerken bij partus     
termijn in weken plus dagen, gemiddelde  
(SD, in dagen) 
39+4(1,4) 39+4(1,7) 39+4(1,5) 
placentagewicht in g,  
gemiddelde (SD) 
622(117) 605(116) 616(117) 
geboortegewicht in g, 
gemiddelde (SD) 
3305(497) 3257(488) 3287(494) 
primaire sectio wegens stuitligging, 
n(%) *** 
92(39) 38(27) 130(35) 
*:  Significant verschillend bij χ2-toets; 1 vrijheidsgraad; 95%-BI: 1,06 - 2,51; p=0,013 
**:  Significant verschillend bij χ2-toets; 1 vrijheidsgraad; 95%-BI: 0,31 - 0,74; p=0,001 
***:  Significant verschillend bij χ2-toets; 1 vrijheidsgraad; 95%-BI: 1,08 - 2,36; p=0,03. 
 
Bij 62 patiënten bleek er bij echoscopische controle al sprake te zijn van een 
hoofdligging van de foetus; 2 patiënten zagen bij nader inzien af van een 




dwarsligging van de foetus; en 2 hadden een contra-indicatie voor versie 
vanwege oligohydramnion. 
De uitkomsten van versie bij de overige 139 vrouwen werden geanalyseerd en 
vergeleken met de uitkomsten van de groep uit de periode 2004-2006 (n = 
236), de periode voordat de procesmatige veranderingen werden doorgevoerd. 
De obstetrische kenmerken van deze 2 groepen staan weergegeven in tabel 1. 
Hieruit blijkt dat de patiëntkarakteristieken voor de groep 2004-2006 vrijwel 
identiek waren aan die van de groep 2007-2008, met uitzondering van 2 
subgroepen bij de termijn bij versie. In de periode 2007-2008 werden er 
namelijk significant meer versies verricht bij een termijn van 36-37 weken dan in 
de periode 2004-2006 en significant minder versies verricht voor een termijn 
van 36 weken. 
In de totale groep (n = 375) kwamen 17 spontane versies voor. Dit betrof bij 9 
patiënten, na mislukte versie, een spontane versie van stuit naar hoofdligging bij 
de partus (4 nulliparae en 5 multiparae). Bij 8 patiënten betrof dit, na geslaagde 
versie, een spontane versie van hoofd naar stuitligging bij de partus (5 nulliparae 
en 3 multiparae). 
 
Figuur 1. Percentages succesvolle uitwendige versies bij stuitligging na oprichting van een 
speciaal versiecentrum in 2004, en het doorvoeren van een aantal procesmatige 
beleidsregels in 2007. 
 
In de figuur is het succespercentage van de versies per jaar weergegeven. Het 
succespercentage over de jaren 2004, 2005 en 2006 verschilde nauwelijks, 
respectievelijk 45, 48 en 41%, maar nam in 2007 abrupt toe (62%), waarna in 
2008 geen verdere stijging waarneembaar was (60%). In tabel 2 is het percentage 
succesvolle versies in de perioden 2004-2006 en 2007-2008 weergegeven, voor 
zowel de groep als geheel, als uitgesplitst naar pariteit en type stuit, en worden 
deze onderling vergeleken. Hieruit blijkt een hoger succespercentage in de 
periode 2007-2008 voor de gehele groep patiënten (61%), alsook voor 




nulliparae en multiparae afzonderlijk, ten opzichte van de periode 2004-2006. 
Verder blijkt dat deze stijging vooral bij de onvolkomen stuit (moeilijke versies) 
werd teruggevonden. Zo nam bij nulliparae met een onvolkomen type stuit het 
succespercentage significant toe van 27 naar 46%, terwijl bij volkomen stuit een 
geringe stijging te zien was van 57 naar 65%. Bij multiparae was er een 
vergelijkbare stijging van het succespercentage bij de onvolkomen stuit van 58 
naar 77%, en een geringe stijging bij de volkomen stuit van 66 naar 78%. 
 
Tabel 2: Overzicht van succesvolle uitwendige versies bij stuitligging, vóór (2004-2006) 
en na (2007-2008) invoering van een procesprotocol, zowel van de patiëntengroep in 
zijn geheel, als opgesplitst naar pariteit en moeilijkheidsgraad. 
 Totaal 
N = 375 
2004-2006 
N = 236 
2007-2008 
N = 139 
p-waarde 95%-BI 
hoofdligging na versie  195 (52) 110 (47) 85 (61) 0,006 1,17 - 2,73 
n (%) totaal      
nullipara  95/225 (42) 51/139 (37) 44/86 (51) 0,03 1,09 - 3,01 
moeilijke versie 
(onvolkomen stuit) 
55/158 (35) 26/95 (27) 29/63 (46) 0,01 1,11 - 3,91 
makkelijke versie 
(volkomen stuit) 
40/67 (60) 25/44 (57) 15/23 (65) 0,5 0,57 - 4,11 
multipara 100/150 (67) 59/97(61) 41/53(77) 0,04 1,06 - 4,08 
moeilijke versie 
(onvolkomen stuit) 
59/92 (64) 36/62 (58) 23/30 (77) 0,08 0,96 - 8,07 
makkelijke versie 
(volkomen stuit) 
41/58 (71) 23/35 (66) 18/23 (78) 0,3 0,68 -4,59 
 
De ruwe OR van het doorvoeren van het procesprotocol op succesvolle versie 
bedroeg 1,61 (95%-BI: 1,03-2,61). In tabel 3 staan de gecorrigeerde OR’s 
weergegeven van geslaagde versie (afhankelijke variabele) bij 375 zwangeren met 
een stuitligging, met het doorvoeren van het procesprotocol als onafhankelijke 
variabele. Daarbij werd gecorrigeerd voor een aantal uit de literatuur bekende 
factoren. Hieruit blijkt dat bij nullipariteit, onvolkomen stuitligging, een placenta 
anterior lokalisatie en een laag geboortegewicht de kans op een succesvolle 
versie afnam, terwijl na implementatie van het procesprotocol deze kans 
toenam. Tevens blijkt uit tabel 3, dat de termijn bij versie, dat wil zeggen voor of 





Tabel 3: Effect van het invoeren van een procesprotocol voor uitwendige versie bij 375 
zwangeren met een stuitligging, weergegeven als gecorrigeerde oddsratio’s (OR), met het 
doorvoeren van het procesprotocol als onafhankelijke variabele multipele logistische-
regressiemodel 
 gecorrigeerde OR 95% - BI 
procesprotocol 1,71 1,12 – 2,87 
leeftijd zwangere 0,98 0,94 – 1,04 
lermijn bij versie: vóór of  na 37 weken 0,94 0,57 – 1,52 
nullipariteit 0,35 0,22 – 0,56 
onvolkomen stuit 0,48 0,30 – 0,77 
placenta anterior 0,64 0,41 – 0,98 
laag placentagewicht* 1,01 0,45 – 2,29 
laag geboortegewicht kind** 0,38 0,16 – 0,89 
*: Laag placentagewicht: gewicht < 10de percentiel ( < 479 gram) van de totale groep 
**: Laag geboortegewicht: gewicht < 10de percentiel ( < 2674 gram) van de totale groep 
 
Over de gehele periode (2004-2008) nam het percentage sectio’s na een 
succesvolle versie af met een factor 6,5: van 79% naar 12%. Het percentage 
primaire sectio’s wegens stuitligging à terme nam na de invoering van het 
procesprotocol significant af: van 39% in de periode 2004-2006 naar 27% in de 
periode 2007-2008 (95%-BI: 1,08-2,36; p = 0,03, zie tabel 1). Dit betekent, dat 
het ‘number needed to treat’ om 1 sectio te voorkomen door middel van 
uitwendige versie volgens het procesprotocol, 8 bedraagt. De reductie van het 
absolute risico op een electieve sectio door een geslaagde uitwendige versie na 
het doorvoeren van het procesprotocol bedroeg 12% (95%-BI: 1,7-21,0). 
 
Beschouwing 
Na invoering van een procesprotocol in het versiespreekuur nam het 
succespercentage van uitwendige versie significant toe van 47 naar 61%. Dit 
resulteerde in een daling van het percentage primaire sectio’s wegens stuitligging 
met 12%. Het blijkt dat vooral een hoger succespercentage werd behaald bij 
zwangeren bij wie de baby in onvolkomen stuit lag. Deze stijging was niet het 
gevolg van een verandering van de samenstelling van de patiëntenpopulatie. 
 
Invloed van wijzigingen op procesniveau 
In de periode 2004-2006 bleek al vrij snel dat in een grote perifere 
opleidingskliniek slechts een beperkt aantal obstetrici routine kunnen krijgen in 
het verrichten van uitwendige versies. Door vanaf 2007 een vast team van 
versiespecialisten te formeren en deze op een vast tijdstip in de week vrij te 
plannen van andere taken binnen de dagelijkse praktijk, werd een hoger 
rendement behaald bij uitwendige versies. 
 
Invloed van weeënremming 
In 2004 werd in ons ziekenhuis als weeënremmer ritodrine (voorheen bekend 
als Prepar) 10 mg intramusculair gebruikt. Vanwege de vervelende, veelal 




cardiale bijwerkingen zoals maternale hartkloppingen, werd ritodrine in februari 
2005 vervangen door atosiban 6,75 mg intraveneus. Tot nog toe is alleen de 
effectiviteit van ritodrine bij versie evidence-based bewezen.9 Echter, een kleine 
retrospectieve analyse waarin 17 patiënten ritodrine kregen toegediend en 21 
patiënten atosiban, liet zien dat beide middelen even effectief lijken.10 
Onze eerste ervaringen met atosiban deden wij op in 2005, toen dit middel 
steeds vaker werd toegediend op het versiespreekuur. Omdat het consequent 
toepassen van atosiban in het nieuwe protocol mogelijk een verklaring zou 
kunnen zijn voor de toename van het succespercentage, werden de data over de 
periode van 2004-2006 nader geëvalueerd. Hieruit bleek dat in 2004 bij 40% van 
de vrouwen tocolyse was toegediend, in 2005 bij 75% en in 2006 bij 97%. Uit de 
figuur blijkt dat het succespercentage gedurende die jaren niet veranderde. Dit 
maakt het onwaarschijnlijk dat een toename van het succespercentage van 
versie na deze periode toe te schrijven is aan het standaard toedienen van 
tocolyse. Uiteraard is alleen een gerandomiseerde klinische trial in staat om het 
onafhankelijk effect van tocolyse op het succespercentage aan te tonen. 
 
Effectiviteit en veiligheid 
Uitwendige versie in een klinische setting is een zeer efficiënte manier om het 
percentage keizersneden bij stuitligging te reduceren.11 Ook in onze studie nam 
het aantal sectio’s fors af, namelijk met een factor 6,5: van 79% bij niet 
succesvolle versie tegen 12% na succesvolle versie. Daarnaast is het ook een 
veilige methode om het aantal keizersneden bij stuitligging te doen dalen.12-15 In 
onze studie trad er gedurende de gehele periode 2004-2008 1 ernstige 
complicatie op, namelijk een partiële abruptio placentae. Na een spoedsectio 
werd een gezond kind geboren, met een apgarscore van 9 en 9 na 
respectievelijk 1 en 5 min. Deze ernstige complicatie impliceert dat een versie in 
een klinische setting dient plaats te vinden.1,16-18 
 
Beperkingen van het onderzoek 
Een beperking van de huidige studie is dat het een niet-gerandomiseerd 
onderzoek betreft, maar deels een retrospectieve (2004-2006), deels een 
prospectieve (2007-2008) studie. Het is echter de vraag of - met de huidige 
gegevens voorhanden - het ethisch nog verantwoord is om een uitwendige 
versie aan te bieden anders dan volgens een strak omlijnd protocol. 
Een andere beperking is het aantal deelnemers in de prospectieve studie: door 
het nog relatief geringe aantal is analyse bij subgroepen, zoals verschillen in de 
termijn bij versie, niet altijd mogelijk. In de literatuur is de invloed van de termijn 
bij versie op het succespercentage nog niet duidelijk.19-20 Op dit moment loopt 
er een gerandomiseerde multicenter studie naar het effect van de termijn op de 
uitkomst van een uitwendige versie, waarvan de resultaten in de loop van 2009 




Tenslotte zijn sommige parameters, waarvan uit de literatuur bekend is dat deze 
een versie kunnen beïnvloeden, zoals de hoeveelheid vruchtwater en de mate 
van indaling van de stuit in het bekken, niet meegenomen, zodat hun 
onafhankelijk effect op het succespercentage binnen het huidige model niet kan 
worden geschat. 
 
Implicaties voor de organisatie van zorg 
Concentratie van zorg komt de kwaliteit ten goede. Zoals de Inspectie voor de 
Gezondheidszorg voorstelt, moeten er binnen het ziekenhuiswezen regionale 
specialistische centra komen voor specifieke ingrepen.21 Het huidige onderzoek 
laat zien dat dit niet alleen geldt voor technisch ingewikkelde operaties, maar 
ook voor relatief eenvoudige handelingen zoals uitwendige versie, waarbij een 
strakke organisatie, gekoppeld aan brede ervaring, in belangrijke mate bijdraagt 
aan het succes van de interventie, met alle positieve gevolgen voor moeder en 




Na het oprichten van een obstetrisch centrum gespecialiseerd in uitwendige 
versies bij stuitligging, waarbij ook op procesniveau beleidsregels werden 
doorgevoerd, was er een sterke toename van het percentage geslaagde versies. 
Dit resulteerde in een aanzienlijke verlaging van het aantal primaire 
keizersneden wegens stuitligging. 
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External cephalic version policy in case of 
breech presentation: a matter of  






In The Netherlands, there is a current controversy regarding the policy of 
external cephalic version (ECV) in case of breech presentation in term 
pregnancies. 1  
The question of where to perform ECV involves aspects of safety, success rate, 
competence, training and cost-effectiveness. In The Netherlands, a woman can 
deliver at home with a community midwife (30%), in hospital with a community 
midwife (10%), or - after referral to an obstetrician - with a hospital midwife 
(10%) or with an obstetrician (50%).2 ECV is an intervention which is 
experienced as an unpleasant and stressful event by the mother.3 A community 
midwife in The Netherlands deals with only 3 to 5 pregnancies complicated by 
breech presentation per year 4, a number which is by far too small to build up 
sufficient experience for performing ECV. Immediate referral to a hospital for 
getting an ECV would also provide a partial solution to the problem as often 
only part of the obstetrical staff members and residents in the Dutch hospitals 
are experienced in performing ECV.  
ECV is a relatively safe procedure, with a rare chance of serious complications, 
resulting in emergency Caesarean section in up to 0.4% of cases. 5 International 
guidelines, therefore, recommend that cardiotocographic monitoring is required 
and that ECV should be attempted only in settings in which Caesarean delivery 
services are available.6,7 The argument by the Royal Dutch Society of Midwives 
favouring current clinical practice regarding ECV is based on a retrospective 
cohort analysis of 958 ECV’s showing a similar incidence of emergency 
Caesarean section as in usual obstetric care.4 This can be regarded as a typical 
example of ‘health professional centred’ thinking: how to convince a woman 
who needs an emergency Caesarean section after ECV that ECV in a community 
setting is nevertheless a safe intervention?  
The success rate of ECV varies between 35 - 86%.7 Tocolysis is associated with 
successful ECV 8, although its precise role within a standard protocol remains to 
be addressed. Administration of (intravenous) tocolytics during ECV, however, 
is not within the routine care of community midwives.  
There is no debate as to whether or not ECV can easily be performed by a 
midwife specifically trained in ECV. Between January 2004 and July 2006, 209 
ECV’s were performed (120 primipara and 89 multipara) according to a 
standardized protocol at the Catharina Hospital (Eindhoven) with the aid of one 
trained hospital midwife and one trained obstetrician. Ninety-six (46%) women 
had a successful ECV: 44 primipara (37%), and 52 (60%) multipara. One 
emergency Caesarean (0.5%) was performed because of placental abruption. All 
women with successful ECV were referred back to the community midwife who 
delivered 45 (46%) of them. After failed ECV, the number of total Caesarean 
sections was 93 (83%) compared to 9 (9%) in women after successful ECV, 
implicating a nine fold reduction, and thus suggesting high cost/effectiveness. The 
number of participants of this follow-up of standardized ECV is clearly too small 
to generalize. The much needed randomised clinical trials (including tocolysis) to 
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provide evidence based data are currently underway. It is nevertheless believed 
that our study indicates that ECV is a safe and highly effective procedure which, 
when performed by trained healthcare professionals, meets the patients’ right 
for optimal obstetrical care. In our perception, this creates a win-win situation 
as the following objectives are met: the community midwife’s policy to deliver as 
many women as possible; the obstetricians’ objective to reduce the number of 
technical interventions, and the health insurer’s wish to achieve optimal care at 
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Maternal thyroid function is related to the 











To investigate the relation between maternal thyroid function and the outcome 
of external cephalic version (ECV) in breech presentation. 
 
Design 
Prospective cohort study in 141 women (> 35 weeks gestation) with a singleton 
foetus in breech. Blood samples for assessing thyroid function were taken prior 
to ECV.  Main outcome measure was the relation between maternal thyroid 
function and ECV outcome indicated by post ECV ultrasound. 
 
Results 
ECV success rate was 77/141 (55%), 41/48 (85%) in multipara and 36/93 (39%) 
in primipara. Women with a failed ECV attempt had significantly higher TSH 
concentrations than women with a successful ECV (p < 0.001). Multiple logistic 
regression showed that TSH (OR: 0.52, 95% CI: 0.30-0.90), nulliparity (OR: 
0.11, 95% CI: 0.03-0.36), frank breech (OR: 0.30, 95% CI: 0.10-0.93) and 
placenta anterior (OR: 0.31, 95% CI: 0.11-0.85) were independently related to 
ECV success.  
 
Conclusion 
Higher TSH levels increase the risk of ECV failure. 
 
 




The incidence of breech presentation decreases with increasing gestational age 
from approximately 16% at 32 weeks to 3-5% of all pregnancies at term.1 
External cephalic version (ECV) is recommended by the American College of 
Obstetricians and Gynecologists (ACOG) 2 and the Royal College of 
Obstetricians and Gynaecologists (RCOG) 3 as the best method to reduce the 
number of breech presentations and breech deliveries at term. Reported 
success rates vary widely from 30-80%.3 Several factors have been associated 
with successful ECV outcome including parity, type of breech, placenta location, 
amniotic fluid index, and engagement of the breech.4-6   
Recently, our research group showed that at 36 weeks gestation women with 
TSH levels above 2.5 mIU/l are at risk for breech presentation.7 It is stated that 
foetal movements and mobility are a prerequisite for spontaneous version into 
the cephalic position.8 Since maternal thyroid function is related to the 
probability of spontaneous version, it may be hypothesized that TSH may, in 
turn, affect ECV outcome. 
To the best of our knowledge, this is the first prospective study to examine the 




Over a period of two years, 194 women seen in a specialized ECV clinic were 
invited to participate when they presented at ≥ 35 weeks gestation with a foetus 
in breech presentation. Only Caucasian patients with sufficient knowledge of the 
Dutch language were eligible (n = 169). Nineteen patients declined to 
participate, while four patients with a transverse lie and five patients with known 
thyroid disease were excluded. Data analysis, therefore, included the remaining 
141 participants (see table 1), all of whom gave written informed consent.  
This study was approved by the Medical Ethical Committee of the Catharina 
Hospital in Eindhoven, The Netherlands. 
 
Assessments 
At intake, demographic features (maternal age, BMI, tobacco/alcohol use) and 
obstetrical parameters (parity, previous obstetrical history) were recorded. 
Prior to ECV, ultrasound was performed to determine type of breech, amniotic 
fluid index and placental location. Ultrasound was repeated post-ECV in order 






Table 1: Characteristics of 141 women who had an ECV attempt and in whom thyroid 
parameters were assessed. 
 Mean (SD) N (%) 
Demographic features   





Any tobacco use                          11(8)                    
Any alcohol use                         12(8.5)                
Body mass index (BMI) 




BMI <25  112 (79.5) 
BMI between 25 and 30  17 (12) 
BMI > 30  12 (8.5) 
Previous miscarriage in life  31(22) 
Obstetrical features   
Parity   
Nulliparity  93 (66) 
Multiparity  48 (34) 
Gestational age at ECV  (weeks, days) 
Range (35.0-39.9) 
36.1 (0.9)  
Type of breech    
Frank                          93 (66) 
Complete                          36 (25.5)                      
Incomplete                         12 (8.5)                     
Placenta location   
Anterior  55 (39) 
Posterior  56 (39.7) 
Lateral  30 (21.3) 
Cephalic presentation after ECV  77 (55) 
Cephalic presentation at delivery  79 (56) 
Placental weight (grams) 




Birth weight (grams)   




Thyroid parameters   
TSH mIU/l 






Median                      




TPO-Ab >35  kU/l           9 (6) 
 
ECV intervention 
Cardiotocography was performed routinely before and after the procedure. 
Before ECV, all women had a full bladder and were routinely given a tocolytic 
drug (Atosiban, 6.75 mg. intravenously). Anti-D (1000 IE) was given 
prophylactically to all Rhesus negative women. ECV (monitored by ongoing 
ultrasound) was performed by two experienced obstetricians working in unison: 
the hands of one staff member concentrated on the breech, while the other’s 
concentrated on the foetal head, with manipulation being consecutive rather 
than simultaneous. While a “forward somersault” was the preferred method to 
achieve cephalic position, a “backward flip” was an alternative strategy for 
nulliparous patients with a frank breech presentation. ECV was defined as 
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Blood samples were taken prior to administration of the tocolytic drug and 
subsequently stored for assessing the following thyroid parameters: thyroxine 
(FT4), thyrotrophin (TSH) and thyroid peroxidase antibodies (TPO-Ab). TSH 
was measured using a solid-phase, two-site chemiluminescent enzyme 
immunometric assay (IMMULITE Third generation TSH, Diagnostic Products 
Corporation, Los Angeles USA). The inter-assay coefficients of variation were 
5.0% and 4.4% at concentrations 0.22 mIU/l and 2.9 mIU/l, respectively. FT4 
concentration was also measured by means of a solid-phase immunometric 
assay (IMMULITE Free T4). The inter-assay coefficients of variation for this 
technique were 6.7% and 4.4% at concentrations of 11.6 pmol/l and 31.5 pmol/l, 
respectively. Reference ranges for non-pregnant women for TSH and FT4 were: 
0.4 - 4.0 mIU/l and 10 - 24 pmol/l, respectively. The IMMULITE TPO-Ab kit was 
used for the determination of antibodies against thyroid peroxidase (TPO). The 
inter-assay coefficients of variation for this analysis were 9% and 9.5% for 
concentrations of 40 kU/l and 526 kU/l, respectively. The anti-TPO assay was 
standardized in terms of the International Reference Preparation for anti-TPO 
MRC 66/387. TPO-Ab concentrations >35 kU/l at 36 weeks gestation were 
regarded as antibody positive. 
 
Statistical analysis 
Statistical analysis was performed using the Statistical Package for the Social 
Sciences (SPSS 17.0). Initial analyses described the sample using means, standard 
deviations and frequencies. The distributions of FT4 and TSH were non-
Gaussian (Kolmogorov-Smirnov tests); therefore, Mann-Whitney U-tests were 
used to examine FT4 and TSH for group comparisons and ECV success. 
Associations among elevated maternal thyroid antibodies (TPO-Ab > 35 kU/l) 
and ECV outcome were analyzed using chi-square tests. Prevalence of successful 
ECV stratified according to quartiles of TSH was also examined using a chi-
square test. Single and multiple logistic regression analysis (odds ratios and 95% 
CI’s) were performed to calculate un-adjusted and adjusted OR’s for successful 
ECV (dependent variable). The independent variable was TSH. For the multiple 
logistic regression analysis, age (continuous), body mass index (continuous), 
parity (dichotomized in nulliparous and parous), type of breech (frank breech 
versus the rest), gestational age at version (continuous), placental position 
(dichotomized in anterior versus other), placental weight (continuous), birth 
weight (continuous) and amniotic fluid index (dichotomized using 10 cm as a 






The overall ECV success rate, indicated by the post-procedure ultrasound 
results, was 55% (77/141), and was significantly lower in nulliparous women 
(39%: 36/93) than in multiparous women (85%: 41/48; χ2 = 27, df = 1, p < 
0.001). In one patient prolonged post-ECV foetal bradycardia occurred which 
necessitated emergency cesarean section. Transient heart rate abnormalities 
were observed in 3 patients. Spontaneous version into cephalic position at birth 
after failed ECV occurred in 2 (nulliparous) women. Spontaneous version back 
into breech after successful ECV did not occur. 
The median TSH level for the whole study sample was 1.48 mIU/l (range: 0.02 - 
10 mIU/l). Table 2 shows the distribution of FT4 and TSH values in relation to 
ECV outcome. Women with failed ECV’s had significantly higher TSH levels than 
those with successful ECV’s (Mann-Whitney U, p < 0.001), but corresponding 
FT4 levels did not differ between groups (Mann-Whitney U, p = 0.88). The 
correlation between FT4 and TSH was 0.18, (p = 0.034). Also, the prevalence of 
elevated TPO-Ab (> 35 kU/l) did not differ between groups (9% versus 4%, p = 
0.18) with regard to ECV outcome. 
  
Table 2: Median and range of FT4, TSH and number of elevated TPO-Ab titres in 141 
breech women in relation to ECV outcome 








Median TSH mIU/l  1.20 1.90 <0.001  
Range 0.02-10.0 0.60-9.20   
Median FT4 pmol/l 10.0 10.0 0.88  
Range 7.2-14.0 7.1-14.2   
TPO-Ab > 35 kU/l  3 (4%) 6 (9%)  0.18 
 
Figure 1 shows the prevalence of successful ECV according to different TSH 
quartiles (25th percentile: < 0.99 mIU/l, 25th - 50th percentile: 0.99 - 1.48 mIU/l, 
50th - 75th percentile: 1.49 - 2.0 mIU/l and > 75th percentile: > 2.0 mIU/l). 
Clearly, the percentage of ECV success significantly decreased with increasing 
TSH quartile (74% to 30%, χ2 = 15, df = 3, p = 0.002). 
 In table 3a, single logistic regression is shown with successful ECV as the 
dependent variable. TSH, parity, type of breech and placenta anterior location 
were all significantly related to successful ECV outcome. In table 3b, adjusted 
OR’s are shown with TSH as independent variable and successful ECV as 
dependent variable using multiple logistic regression analysis. TSH (OR: 0.52, 
95% CI: 0.30-0.90), nulliparity (OR: 0.11, 95% CI: 0.03-0.36), frank breech (OR: 
0.30, 95% CI: 0.10-0.93) and placenta anterior (OR: 0.31, 95% CI: 0.11-0.85) 
were all significantly and independently related to ECV success. 
 In healthy pregnant women (without elevated concentrations of TPO-Ab and 
with proven sufficient iodine intake) trimester specific cutoffs for elevated TSH 
are still lacking. A frequently used upper TSH reference level in pregnancy  
Maternal thyroid function is related to the outcome of ECV in breech presentation 
109 
 
is ≥ 2.5 mIU/l.9 In the current study 20 women had a TSH above this level. Of 
these 20 women 5 (25%) underwent successful ECV, compared to 72 successful 
ECVs from the sample of 121 women (60%) with TSH levels below the cutoff of 
2.5 mIU/l (χ2 = 8.2, df = 1, p = 0.004). The RR of women in breech with TSH 
above 2.5 mIU/l for failed ECV was 2.4, (95% CI = 1.1 - 5.3). 
 
Figure 1: percentage of ECV success in relation to TSH quartiles (mIU/l) in 141 women 
with breech presentation ≥ 35 weeks gestation * 
 
• chi-square = 15, df=3, p =0.002 
 
Discussion 
In the current study, successful ECV outcome was independently related to 
maternal TSH: women with unsuccessful ECV had significantly higher TSH levels. 
 The ECV success rate of 55% in the current study is comparable to others 
reported in the literature.2,3 While our data support earlier observations 
showing that factors affecting ECV success include parity, type of breech and 
placenta location 4-6, to our knowledge, this is the first study reporting on a 
possible relationship between maternal thyroid function and ECV outcome.  
 We recently showed in a large sample of over 1000 pregnant women from the 
general population that higher levels of TSH constitutes a risk factor for breech 
presentation.7 The median TSH of breech-presenting women (n = 58) in that 
sample was 1.47 mIU/l which is remarkably similar to the median TSH value of 
1.48 mIU/l obtained in the current sample of 141 women presenting in breech.  
How can the observed relationship between maternal TSH and ECV outcome 
be explained? Several mechanisms might be suggested. First, one could argue 
that elevated maternal TSH directly impacts uterine relaxation, thereby 
negatively affecting ECV outcome. Empirical evidence regarding such a direct 
effect is, however, scarce. TSH receptors have been shown in other non-thyroid 
tissues such as bone, heart and brain tissue, but so far no studies on human 




hypothyroidism (reflected by high TSH), the myocytes of the smooth muscle 
cells of the aorta are dysfunctional,  leading to increased arterial stiffness and  
impaired diastolic function.12 The mechanism behind is a reduced activity of the 
sarcoplasmatic reticulum CA-ATPase which controls the efficient concentration 
of calcium in the cytoplasm. Another study in sub-clinical hypothyroid women 
showed a beneficial effect of thyroxine replacement on arterial stiffness.13 It is 
known from earlier studies that thyroid hormone (T3) has a direct relaxation 
effect on vascular smooth muscle cells.14 It might be hypothesized that a similar 
relation between TSH and uterine myocytes does exist. Inappropriate relaxation 
of uterine smooth muscle vessels in women with high TSH might hinder ECV.  
  
Table 3: Unadjusted (A) and adjusted OR’s (B) for successful outcome of ECV 
(dependent variable), n = 141 
A  OR 95% CI 
Maternal age 1.05 0.97-1.14 
Body Mass Index 0.93 0.86-1.02 
Gestation at version  1.05 0.73-1.50 
Nulliparity 0.12 0.05-0.29 
Frank breech 0.37 0.18-0.78 
Amniotic fluid  > 10 cm 1.33 0.67-2.65 
Placenta anterior 0.36 0.18-0.74 
Placental weight 1.00 0.99-1.01 
Birth weight 1.001 1.00-1.002 
TSH  0.59 0.41-0.88 
FT4 1.03 0.83-1.29 
B  OR 95% CI 
Maternal age 1.02 0.91-1.14 
Body Mass Index 0.88 0.76-1.01 
Gestation at version 0.91 0.53-1.56 
Nulliparity 0.11 0.03-0.36 
Frank breech 0.30 0.10-0.93 
Amniotic fluid index > 10 1.21 0.51-2.34 
Placenta anterior 0.31 0.11-0.85 
Placental weight 0.99 0.98-1.01 
Birth weight  1.001 1.000-1.002 
TSH 0.52 0.30-0.90 
FT4 1.15 0.82-1.61 
 
Another candidate mechanism might relate to foetal motility and its ability to 
facilitate spontaneous version. High maternal TSH during gestation has been 
associated with impaired neonatal motor function.15 One may argue that higher 
levels of maternal TSH could conceivably reflect low circulating foetal T4 levels. 
Shortage of foetal T4 compromises foetal neural maturation and, in turn, foetal 
motility through its effects on muscle tone and reflexes.16 Furthermore, breech 
babies tend to be smaller17, have lower scores on neuromotor tests18,19 , and are 
balanced-impaired until the age of 12-18 months.20 Their impaired neuromotor 
development could in fact hinder ECV outcome. The current study findings did 
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not reveal differences in FT4 level between the successful versus the 
unsuccessful ECV groups. This may have been due to the greater sensitivity of 
TSH - compared to FT4 - to detect small changes in the set point of the 
hypothalamus-pituitary-thyroid axis.21 Moreover, it has been reported that 
pregnancy FT4 assessments are less reliable than non-pregnancy assessments.22 
Also in this study a weak correlation (r = 0.18, p = 0.34) was found between 
FT4 and TSH, but in the opposite direction of what would be expected: 
normally there is an inverse correlation between TSH and FT4. 
Despite growing insight into the prognostic factors of successful ECV, no 
scoring system that accurately predicts success exists.23-26 A recent study shows 
that if the estimated probability of success is less than 32%, an ECV attempt is 
not cost effective with poorer quality-adjusted life-years (QALYs) for the 
patient when compared to a caesarean section.27 It may well be that the 
inclusion of maternal TSH in improved cost-effectiveness analyses would lead to 
enhanced probability-of-ECV success estimates.  
A limitation of the current study relates to the fact that iodine excretion data in 
mothers and neonates were not assessed. This made it impossible to relate 
higher TSH levels to inadequate iodine intake during gestation. A major strength 
of the current study was its relatively large sample size and the fact that ECV 
was performed in one obstetric department by a small team of trained experts 
following the same protocol and blind to the thyroid status of the patients.  
In conclusion, the current study is among the first to report a possible 
relationship between maternal thyroid function and ECV outcome. While the 
study suggests that higher levels of TSH are independently related to ECV 
outcome, the precise mechanism behind this finding remains to be determined. 
 
Acknowledgements: We wish to acknowledge the support of the Scientific 







 1  Hill LM. Prevalence of breech presentation by gestational age. Am J Perinatol 1990;7(1):92-
3. 
 2  Royal College of Obstetricians and Gynaecologists. External cephalic version and reducing 
the incidence of breech presentation. Guideline No. 20A. 2006.  
 3  ACOG Practice Bulletin. External Cephalic Version. Clinical Management Guidelines for 
Obstetrician-Gynecologists Number 13, February 2000. Obstetrics & Gynecology 
2000;95(2):1-7. 
 4  Kok M, Cnossen J, Gravendeel L, van der Post J, Opmeer B, Mol BW. Clinical factors to 
predict the outcome of external cephalic version: a metaanalysis. Am J Obstet Gynecol 
2008;199(6):630-7. 
 5  Kok M, Cnossen J, Gravendeel L, van der Post J, Mol BW. Ultrasound factors to predict 
the outcome of external cephalic version: a meta-analysis. Ultrasound Obstet Gynecol 
2009;33(1):76-84. 
 6  Ben-Meir A, Erez Y, Sela HY, Shveiky D, Tsafrir A, Ezra Y. Prognostic parameters for 
successful external cephalic version. J Matern Fetal Neonatal Med 2008;21(9):660-2. 
 7  Kuppens SM, Kooistra L, Wijnen HA, Crawford S, Vader HL, Hasaart TH, Oei SG, Pop VJ. 
Maternal thyroid function during gestation is related to breech presentation at term. Clin 
Endocrinol (Oxf) 2010;72(6):820-4. 
 8  Witkop CT, Zhang J, Sun W, Troendle J. Natural history of fetal position during pregnancy 
and risk of nonvertex delivery. Obstet Gynecol 2008;111(4):875-80. 
 9  Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, et al. 
Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine 
Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92(8 Suppl):S1-47. 
 10  Peeters RP, van der Deure WM, Visser TJ. Genetic variation in thyroid hormone pathway 
genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur J 
Endocrinol 2006;155(5):655-62. 
 11  Heemstra KA, van der Deure WM, Peeters RP, Hamdy NA, Stokkel MP, Corssmit EP, et 
al. Thyroid hormone independent associations between serum TSH levels and indicators of 
bone turnover in cured patients with differentiated thyroid carcinoma. Eur J Endocrinol 
2008;159(1):69-76. 
 12  Papi G, Uberti ED, Betterle C, Carani C, Pearce EN, Braverman LE, et al. Subclinical 
hypothyroidism. Curr Opin Endocrinol Diabetes Obes 2007;14(3):197-208. 
 13  Owen PJ, Rajiv C, Vinereanu D, Mathew T, Fraser AG, Lazarus JH. Subclinical 
hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab 
2006;91(6):2126-32. 
 14  Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth 
muscle. Thyroid 1996;6(5):505-12. 
 15  Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. J 
Neuroendocrinol 2008;20(6):784-94. 
 16  Wijnen HA, Kooistra L, Vader HL, Essed GG, Mol BW, Pop VJ. Maternal thyroid hormone 
concentration during late gestation is associated with foetal position at birth. Clin 
Endocrinol (Oxf) 2009;71:746-51. 
 17  Luterkort M, Polberger S, Persson PH, Bjerre I. Role of asphyxia and slow intrauterine 
growth in morbidity among breech delivered infants. Early Hum Dev 1986;14(1):19-31. 
 18  Kean LH, Suwanrath C, Gargari SS, Sahota DS, James DK. A comparison of fetal behaviour 
in breech and cephalic presentations at term. Br J Obstet Gynaecol 1999;106(11):1209-13. 
 19  Molkenboer JF, Roumen FJ, Smits LJ, Nijhuis JG. Birth weight and neurodevelopmental 
outcome of children at 2 years of age after planned vaginal delivery for breech 
presentation at term. Am J Obstet Gynecol 2006;194(3):624-9. 
 20  Sival DA, Prechtl HF, Sonder GH, Touwen BC. The effect of intra-uterine breech position 
on postnatal motor functions of the lower limbs. Early Hum Dev 1993;32(2-3):161-76. 
Maternal thyroid function is related to the outcome of ECV in breech presentation 
113 
 
 21  Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ. Higher maternal TSH 
levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal 
death. Eur J Endocrinol 2009;160(6):985-91. 
 22  Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, et al. Free T4 
immunoassays are flawed during pregnancy. Am J Obstet Gynecol 2009;200(3):260-6. 
 23  Newman RB, Peacock BS, VanDorsten JP, Hunt HH. Predicting success of external cephalic 
version. Am J Obstet Gynecol 1993;169(2 Pt 1):245-9. 
 24  Lau TK, Lo KW, Wan D, Rogers MS. Predictors of successful external cephalic version at 
term: a prospective study. Br J Obstet Gynaecol 1997;104(7):798-802. 
 25  Wong WM, Lao TT, Liu KL. Predicting the success of external cephalic version with a 
scoring system. A prospective, two-phase study. J Reprod Med 2000;45(3):201-6. 
 26  Chan LY, Leung TY, Fok WY, Chan LW, Lau TK. Prediction of successful vaginal delivery 
in women undergoing external cephalic version at term for breech presentation. Eur J 
Obstet Gynecol Reprod Biol 2004;116(1):39-42. 
 27  Tan JM, Macario A, Carvalho B, Druzin ML, El-Sayed YY. Cost-effectiveness of external 





























This thesis focuses on the interrelated topics of breech presentation, maternal 
and neonatal thyroid function and determinants of successful ECV. 
In chapter 3, the relationship between suboptimal maternal thyroid function 
during gestation and breech presentation at term was studied. Compared to 
women with foetuses in the cephalic presentation, those women who presented 
with a foetus in breech presentation at term had significantly higher TSH 
concentrations, but only at 36 weeks gestation (p = 0.007). No between group 
differences were obtained for FT4 level at any assessment. Women with TSH 
concentrations below the 5th percentile had no breech presentations. Breech 
presentation was significantly and independently related to high-normal maternal 
TSH concentration (≥ 2.5 mIU/l) at 36 weeks gestation (OR: 2.23, 95% CI: 1.14 
- 4.39), but not at 12 and 24 weeks gestation. Women with TSH levels above 
2.5 mIU/l during end gestation were at risk for breech presentation, and as such 
for obstetric complications. 
How can the observed relationship between maternal TSH and foetal breech 
presentation be explained? First, uterine contractions are important for final 
cephalic presentation at term, as was suggested by a large Norwegian study 
including over 45,000 breech cases.1 Elevated maternal TSH might affect uterine 
contractility. In animal studies, hypothyroidism leads to impaired uterine 
contractility.2,3 Second, high maternal TSH during gestation has been associated 
with impaired neonatal motor function.4-6 If impaired motor development in the 
offspring is related to low maternal thyroid hormone concentrations during 
gestation, then similar motor deficits during gestation might affect foetal motility 
and hence interfere with spontaneous rotation from breech into cephalic 
presentation. 
Evidence is accumulating for a direct effect of TSH (other than by increasing T4 
production) in other tissues than thyroid tissue, such as bone and heart7,8, 
although a TSH receptor (TSHR) in myometrium has not yet been described. 
Future (animal) studies are needed to evaluate the direct effect of TSH on 
uterus tonus and contractility. 
How can high-normal TSH in women be explained? First, the finding that high-
normal TSH is strongly associated with higher prevalence rates of elevated 
TPO-Ab concentrations suggests an auto-immune origin: women with high TSH 
in fact are women with high risk for auto-immune hypothyroidism. Because TSH 
assessment is much more sensitive than FT4 assessment to detect women with 
even minor thyroid dysfunction, high-normal TSH (definitely in TPO-Ab positive 
women) should be regarded as a high risk for inappropriate thyroid hormone 
production and hence sub-optimal T4 supply to the foetus. Secondly, high-
normal TSH might be caused by inappropriate iodine intake during pregnancy. 
Iodine excretion data in mothers and neonates were not collected in the 
present study. Although all participants lived in iodine sufficient areas, one may 
question whether adequate iodine intake outside pregnancy also guarantees 




demands. Finally, high-normal TSH might also reflect a maternal physiological 
response to supply the foetus with appropriate amounts of T4. In view of this, it 
is important to note that a substantial part of the maternal T4 supply is 
inactivated in the placenta through deiodinase. This means that different 
placental deiodinase activity levels may interfere with T4 supply and hence with 
maternal TSH. Unfortunately, most of the deiodinase placental pathways are still 
unknown. 
The reason why only high-normal TSH at 36 weeks was related to foetal 
presentation and not at 12 and 24 weeks gestation is intriguing but difficult to 
explain. During early gestation, HCG production interferes with TSH which 
means that at this trimester, maternal TSH levels are less reliable in predicting 
foetal thyroid hormone supply. Another explanation could be that the period of 
high-normal TSH is of importance. In this light it is interesting to note that the 
pattern of T4 fluctuations during gestation was directly related to 
neurodevelopment of the offspring.9 Women with low T4 during early gestation 
but who were able to increase (spontaneously) their T4 levels towards end 
gestation showed no neurodevelopmental delay in the offspring while women in 
whom T4 levels decreased further during gestation had infants at one and two 
year with important neurodevelopmental delay. Future studies therefore, should 
also concentrate on TSH (and FT4 patterns) during gestation rather than 
trimester specific TSH (FT4) concentrations.          
Although this is a large sample of over 1000 women, the obtained number of 
breech presentations is relatively low. The current study may, therefore, be 
criticized for having relatively low epidemiological power. Future research, 
therefore, awaits replication with large size prospective studies, in which thyroid 
parameters of pregnant women presenting in breech are compared with those 
of women presenting in cephalic presentation. In those studies, other possible 
determinants of breech presentation such as umbilical cord length and amniotic 
fluid volume should then also be examined. 
In chapter 4, we investigated whether high-normal maternal TSH is related to 
breech presentation. Enhanced statistical power was achieved by combining two 
prospective studies on women from the same region using similar thyroid 
assessments. Overall, we compared the thyroid data of 189 women with a 
foetus in breech presentation at 35 - 38 weeks gestational age with those of 
1000 women who presented with a foetus in cephalic presentation. Again, 
women with breech presentation had significantly higher mean TSH values.  
Subsequently, we reviewed the literature and found multiple studies reporting a 
relationship between breech presentation and compromised foetal, neonatal or 
infant neurological development. Our finding that breech presentation and high-
normal TSH are related, together with other findings showing that impaired 
neurological development (including autism) and suboptimal maternal thyroid 




neurological development may, in fact, be mediated by maternal thyroid 
hormone (dys)function.   
Our findings reported in chapter 3 and 4 may have future clinical implications. 
Large-scale prospective studies are necessary to investigate whether antenatal 
iodine supplementation and / or T4 replacement therapy could decrease the 
number of breech presentations at term. If this would be the case, an important 
argument in favor of routine maternal thyroid function screening during early 
gestation may be added to the debate in the literature on this topic. 
In chapter 5, we studied the relation between newborn screening data for 
congenital hypothyroidism (CH) and maternal thyroid parameters (i.e., TSH, 
FT4 and TPO-Ab) assessed at 12, 24 and 36 weeks gestation.  
Lower screening TT4 levels were independently related to both high-normal 
maternal TSH levels (at one or more times during pregnancy) and lower 
gestational age. Furthermore, boys had lower screening TT4 levels and their 
mothers had higher TSH levels at 24 and 36 weeks gestation. 
High-normal maternal TSH reflecting lower maternal FT4 levels at early 
gestation may be indicative of reduced FT4 availability for the foetus throughout 
pregnancy, which, in turn, may result in lower neonatal screening TT4 levels. 
Regarding gestational age, it is known that the foetal synthesis of both T4 and 
TSH increases with increasing gestational age.10 To our knowledge, this is the 
first report describing higher TSH levels in pregnant women carrying a male 
foetus. An explanation for this finding is lacking, but one may speculate that male 
foetuses have a more active deiodinase activity than female foetuses, given 
existing reports that boys have lower neonatal TT4 levels (and higher cord 
TSH) than girls.11-13  
We did not analyse iodine excretion in mothers nor neonates. One may argue 
that increased maternal TSH levels and lower neonatal heel TT4 
levels/concentrations reflect the same underlying mechanism: sub-optimal iodine 
intake. Second, we did not analyse thyroid cord blood concentrations, so we 
could not establish whether the obtained association between high-normal 
maternal TSH and low neonatal TT4 is already present in utero. It is important 
to recognize that low maternal thyroid hormone levels during gestation may not 
result in low foetal thyroid hormone levels per se. It is, for instance, well 
established that healthy individuals from iodine deficient areas (e.g., sub-optimal 
iodine intake) are able to provisionally increase their thyroid hormone 
production. Third, trimester-specific reference ranges of TSH and FT4 (taking 
into account iodine intake and the presence/absence of TPO-Ab) do not exist. 
Using the 5% extremes derived from the group of TPOAb-negative women (as 
done in the general population) appears to be the most valid approach currently 
available. Fourth, amniotic fluid data or newborn T3 values to support the 
hypothesis of a more active deiodinase activity in male compared to female 




Whether our finding of lower neonatal screening TT4 levels is clinically relevant 
in terms of a possible negative impact on infant neurodevelopment, remains 
unresolved. With regard to the obtained sex difference in neonatal TT4 
screening levels, it would be interesting to study whether lower TT4 levels in 
boys are associated with increased levels of neurodevelopmental impairment 
commonly found in boys compared with girls. Future research should also link 
TSH-based neonatal screening values to maternal thyroid function during 
pregnancy. The finding of both lower neonatal TT4 levels in boys and higher 
TSH levels in mothers carrying boys is worthy of further investigation, as both 
observations may be meaningfully related. Similarly, relating maternal thyroid 
function, assessed at different trimesters, with cord blood en neonatal screening 
TT4, might elucidate the mechanism by which sub-optimal maternal thyroid 
function relates to neonatal screening TT4. 
In chapter 6, determinants affecting the outcome of external cephalic version 
(ECV) in breech presentation were identified: nulliparity, frank breech 
presentation and low birth weight of the baby were associated with a lower 
ECV success rate. In the group with a successful ECV the percentage of 
caesarean deliveries was substantially lower. A regular team of a trained hospital 
midwife and a gynaecologist working according to a standardized ECV protocol 
proved successful: the number of term breech presentations substantially 
diminished and, consequently, the percentage of caesarean sections was lower in 
the successful ECV group. We do not know the number of women potentially 
suitable for ECV who were not offered an attempt of ECV. Whether selection 
bias occurred is, thus, not known. Because our study had a retrospective study 
design potential selection bias, confounding factors and data quality could not be 
optimally controlled for. 
Introduction of regular ECV teams, working according to a standardized ECV 
protocol may have a significant and positive impact on health care provision in 
the Netherlands in terms of reduced maternal morbidity and cost savings. 
ECV is a relatively easy procedure with potential serious consequences on 
delivery mode. ECV, therefore, should be performed by trained healthcare 
professionals. These professionals can be either obstetricians or midwifes. ECV 
is a relatively safe procedure, with a rare chance of serious complications, and a 
likelihood of emergency caesarean section in up to 0.4% of cases.14,15 
International guidelines recommend cardiotocographic monitoring, and that 
ECV should only be performed in medical settings in which caesarean delivery 
services are available.16-18 Whether tocolysis should be used routinely or 
selectively cannot be answered from this study but only from an RCT. 
In chapter 7, implementing process policy guidelines (PPG), resulted in a 
considerable increase of the ECV success rate. This increase was paralleled by 
an increase of cephalic presentations at delivery and a decrease in the number 
of elective caesarean sections for breech presentation. After implementing PPG 




presentation decreased from 39 to 27%. The increase in ECV success was 
especially found in nulliparous and multiparous women with a frank breech 
presentation. Whether routine administration of tocolysis (Atosiban, 6,75 mg. 
intravenously) results in favorable outcome of ECV could not be answered in 
the current study and would require an RCT. An RCT would also be needed to 
establish whether the improved ECV results could be directly related to the 
implementation of the PPG.   
Given the substantial decrease of caesarean sections and the related cost 
reductions, the current findings already now make a clear case for establishing 
specialized ECV centers in The Netherlands. ECV should be offered to each 
pregnant woman with breech presentation without contra-indications at end 
term. Local policies should be implemented to actively increase the number of 
women who are offered ECV. Finally, ECV should be performed in a hospital 
setting, in which monitoring facilities and facilities for caesarean delivery are 
available. 
In chapter 9, we studied the relation between maternal thyroid function and 
the outcome of ECV in breech presentation. 
Women with a failed ECV attempt had significantly higher TSH concentrations 
than women with a successful ECV, while FT4 did not differ between the 
groups. 
As high-normal maternal TSH has been associated with a reduced likelihood of 
spontaneous cephalic version19, it could also be a factor in ECV outcome. 
Several mechanisms might be suggested. First, one could argue that elevated 
maternal TSH directly impacts uterine relaxation, thereby negatively affecting 
ECV outcome. Empirical evidence regarding such a direct effect is, however, 
scarce. TSH receptors have been shown in other non-thyroid tissues such as 
bone, heart and brain tissue, but so far no studies on human uterine samples 
have been published.7,8  Also, in patients with subclinical hypothyroidism 
(reflected by high TSH), the myocytes of the smooth muscle cells of the aorta 
are dysfunctional,  leading to increased arterial stiffness and  impaired diastolic 
function.20 The mechanism behind is a reduced activity of the sarcoplasmatic 
reticulum CA-ATPase which controls the efficient concentration of calcium in 
the cytoplasm. Another study in sub-clinical hypothyroid women showed a 
beneficial effect of thyroxine replacement on arterial stiffness.21 It is known from 
earlier studies that thyroid hormone (T3) has a direct relaxation effect on 
vascular smooth muscle cells.22 It might be hypothesized that a similar relation 
between TSH and uterine myocytes does exist. Inappropriate relaxation of 
uterine smooth muscle vessels in women with high TSH might hinder ECV.  
Another candidate mechanism that may account for the obtained relationship 
between maternal TSH and ECV outcome might relate to foetal motility and its 
ability to facilitate spontaneous version. High maternal TSH during gestation has 




high-normal maternal TSH could also be associated with impaired foetal motor 
function, and hence predispose for breech presentation.  
Future strategies for optimizing ECV outcome should take into account the 
possible role of maternal thyroid (dys)function. 
 
In conclusion: this thesis has two major outcomes. 
First, maternal thyroid function during gestation may be an important 
determinant of foetal presentation. RCT’s are warranted to investigate the 
effect of (sub)optimal maternal thyroid function on foetal presentation. The 
question whether this should be performed by supplementing T4, iodine or 
both remains, however, to be resolved.   
Secondly, this thesis makes a strong case for offering all pregnant women in 
breech presentation an ECV attempt in specialized ECV centres in which a 
standardized ECV protocol is applied by experienced obstetricians (MD or 
midwives). Serious complications, albeit rare, do occur after ECV, with 
emergency caesarean section as a likely consequence. ECV attempts should, 
thus, be performed in a hospital setting. Again, the possible role of maternal 
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Since the publication of a randomized multicenter international trial called “ the 
Term Breech Trial” (TBT), the percentage of caesarean delivery (CD) for 
breech presentation has strongly increased in the Netherlands. In this study it 
was concluded that compared with vaginal delivery, planned CD was safer for 
the term breech foetus. As a result, there was a high increase in the number of 
CD’s for breech presentation in The Netherlands in October 2000. 
External cephalic version (ECV) is a method to avoid breech presentation, and 
hence CD. 
From studies it appears that ECV is the most efficient and safe method to 
reduce the number of breech deliveries. International guidelines therefore 
advise ECV in case of breech presentation. This thesis is a research on several 
aspects of breech presentation and ECV. Furthermore, this thesis clarifies the 
consequences of suboptimal maternal thyroid function for the child, in particular 
the relation between maternal thyroid function and breech presentation. 
 
In chapter 1, the introduction, an overview is given on three aspects which 
come along with breech presentation. Firstly pathophysiology, epidemiology, 
etiology, spontaneous course of breech presentation and the consequences of 
breech presentation for mother and child are described. Subsequently, the role 
of maternal thyroid function is illustrated and the consequences of suboptimal 
thyroid function for child brain development (motor, behavior and intellect) are 
summarized. At last, an overview of several aspects of ECV, such as history, 
procedure, in- and exclusion criteria, safety, effectiveness and determinants for 
successful outcome of ECV is given. 
 
In chapter 2 the study design is explained. 
 
In chapter 3 the relationship between suboptimal maternal thyroid function 
during gestation and breech presentation at term is presented.  A total of 1058 
Dutch Caucasian healthy pregnant women were prospectively followed from 12 
weeks gestation until term (≥ 37 weeks) delivery. Maternal thyroid parameters 
(TSH, FT4 and TPO-Ab) were assessed at 12, 24 and 36 weeks gestation. At 
term, 58 women (5.5%) presented with a foetus in breech presentation. 
Compared to women with a foetus in cephalic presentation, those women who 
presented with a breech presentation at term had significantly higher TSH 
concentrations at 36 weeks gestation (p = 0.007). No between group 
differences were obtained for FT4 level at any assessment. The prevalence of 
breech presentation in the subgroup of women with TSH ≥ 2.5 mIU/l (90th 
percentile) at 36 weeks gestation was 11%, compared to 4.8% in the women 
with TSH < 2.5 mIU/l (p = 0.006). Women with TSH below the 5th percentile 
had no breech presentations. Breech presentation was significantly and 
independently related to nulliparity (OR: 2.71, 95% CI: 1.17 - 5.50), smoking 





high-normal maternal TSH concentration (≥ 2.5 mIU/l) at 36 weeks gestation 
(OR: 2.23, 95% CI: 1.14 - 4.39), but not at 12 and 24 weeks gestation. In 
conclusion: women with TSH levels above 2.5 mIU/l at end gestation are at risk 
for breech presentation, and as such for obstetric complications. 
  
In chapter 4  the relation between high-normal maternal TSH and breech 
presentation in a larger sample by combining two studies (chapter 3 and 9) is 
described. Therefore maternal thyroid parameters (TSH, FT4 and TPO-Ab) at 
term between a group of 189 women with a foetus in breech presentation and 
1000 women with cephalic lying foetuses were compared. Women with  breech 
presentation had significantly higher mean TSH levels compared to women with 
cephalic lying foetuses. When different cutoff levels were used to define high-
normal TSH (> 90th percentile: TSH > 2.5 mIU/l, 95th percentile: TSH > 2.9 
mIU/l and 97.5th percentile: TSH> 3.4 mIU/l) breech presentation occurred 
significantly more often above the cutoff compared to below the cutoff level. A 
review of the literature showed that in a substantial number of reports a 
relation has been shown between breech presentation and neuro-
developmental delay in the offspring. Because neurodevelopmental delay is also 
related to high(-normal) maternal TSH during gestation, it might be suggested 
that sub-optimal maternal thyroid function in fact explains the relation between 
breech and impaired neuro-development.  
  
  
Chapter 5 describes the relationship between maternal thyroid function at 
each pregnancy trimester and neonatal screening results. A prospective follow-
up study during three trimesters of gestation in 886 Dutch Caucasian healthy 
pregnant women followed from 12 weeks gestation until term delivery (≥ 37 
weeks) and their neonates was performed. Main outcome measure was the 
relation between neonatal data from the congenital hypothyroidism (CH) 
screening and maternal thyroid determinants (TSH, FT4 and TPO-Ab) assessed 
at 12, 24 and 36 weeks gestation. Results show that boys have lower screening 
TT4 levels and their mothers have higher TSH levels at 24 and 36 weeks 
gestation. Lower screening neonatal TT4 levels are independently related to 
high-normal maternal TSH levels (> 97.5th percentile) at one or more times 
during pregnancy (OR: 2.26, 95% CI: 1.20 - 4.29) and lower gestational age at 
delivery (OR: 0.82, 95% CI: 0.71 - 0.95). In conclusion: maternal thyroid function 
during gestation is related to neonatal TT4 at screening. The finding of both 
lower neonatal TT4 levels in boys and higher TSH levels in mothers carrying 
boys compared to mothers carrying girls is worthy of further investigation, as 
both observations may be meaningfully related.  
 
In chapter 6, determinants affecting the outcome of ECV in breech 





standardized protocol in an outpatient clinic - on the mode of delivery is 
evaluated. 
Study design is a retrospective analysis of ECV performed in the Catharina 
Hospital in Eindhoven, The Netherlands. In 2003 a standardized protocol of 
ECV was developed; it was tested in ‘version office visits’. In this standardized 
protocol ECV was performed by two practitioners, one of which was a member 
of the team of three experienced obstetricians trained in ECV. The other 
practitioner was recruited from the staff members of the Ob/Gyn department, 
not specially trained in ECV. Tocolysis was not given routinely, but only in 
selected cases in which difficulty was anticipated or initial attempts failed. 
Obstetric characteristics of all pregnant women who underwent attempts of 
ECV in the clinic from January 2004 until June 2006 during these sessions, and 
the subsequent births, were analysed. In accordance with the protocol, 85% of 
all ECVs were performed by the same hospital midwife and gynaecologist. ECV 
was successful in 96 of 209 pregnant women (46%). In one patient a partial 
abruption placentae occurred resulting in an emergency caesarean section. 
Nulliparity, frank breech presentation and low birth weight of the baby were 
associated with a lower success rate of ECV in this study. In the group with a 
successful ECV, the percentage of caesarean deliveries was substantially lower 
(9 versus 83%; OR: 0.21; 95% CI: 0.09-0.51).  
In conclusion: a regular team consisting of a hospital midwife and a gynaecologist 
working according to a standardized protocol for ECV in case of breech 
presentation proved successful: the number of term breech presentations 
substantially diminished and therefore the percentage of caesarean sections was 
lower in the group in which ECV had been successful. This could have 
considerable impact on health care in The Netherlands in terms of reduced 
maternal morbidity and cost savings. 
 
In chapter 7 the effect of implementation of a number of process policy 
guidelines (protocol), on the success rate of ECV for breech presentation is 
evaluated. The changes in the original protocol could be summarized by four 
R’s: regularity, routine, release and relaxation.  
• Regularity means that ECV is done at a regular basis every week at fixed dates.  
• Routine means that ECV is performed by a fixed team of 4 experienced 
practitioners (2 gynaecologists and 2 midwives).  
• Release means that these practitioners have been released from other 
activities.  
• Relaxation means that tocolysis (Atosiban, 6,75 mg. intravenously) is 
administered routinely. 
After implementing this modified protocol as 'process policy guidelines' (PPG), 
the effect on the rate of successful ECV was prospectively evaluated during the 
period 1 January 2007-31 July 2008. ECV success was defined as cephalic 





was the elective caesarean section rate for breech presentation. The rate of 
successful ECV increased significantly from 47% (110/236 pregnant women) in 
the period January 2004 - December 2006 to 61% (85/139, p = 0.006) in the 
period January 2007 - July 2008. Patient characteristics were similar in both 
groups, with the exception of a small difference in gestational age at ECV. The 
increase was preferentially found in nulliparous and multiparous women with 
frank breech. Nulliparity, frank breech, placenta anterior and low birth weight 
were factors associated with a lower success rate of ECV. After implementing 
PPG compared to the standardized protocol, the number of cephalic 
presentations at delivery increased and the CD rate for breech presentation 
decreased from 39 to 27% (p = 0.03). Conclusion: after implementation of the 
process policy guidelines, the success rate of ECV increased considerably. The 
rate of elective caesarean section for breech presentation declined. These 
findings are in favor of establishing specialized ECV centers in The Netherlands. 
 
Chapter 8 is a comment on the question where ECV should be performed (in 
or outside a hospital) and who should perform it (midwife or gynaecologist). In 
the Netherlands, there is a controversy regarding the policy of ECV in case of 
breech presentation in term pregnancies.  
ECV is a relatively safe procedure, with a pooled complication rate of 6.1%, 
resulting in emergency caesarean section in up to 0.4% of cases. International 
guidelines recommend that cardiotocographic monitoring is required and that 
ECV should be attempted only in settings in which caesarean delivery services 
are available. Furthermore, tocolysis is associated with higher success rates. 
Administration of (intravenous) tocolytics during ECV, however, is not within 
the routine care of Dutch community midwives. So, in conclusion, ECV should 
be performed in a hospital.     
 
ECV is a relatively easy procedure but the outcome has serious impact on the 
mode of delivery of the woman. Therefore, ECV should only be performed by 
trained healthcare professionals with sufficient experience. These professionals 
can be either obstetricians of midwives. 
 
Chapter 9 reports on a possible relationship between maternal thyroid 
function and the success of ECV. Since maternal TSH is related to the 
probability of breech presentation and hence spontaneous version (chapter 3), it 
might be hypothesised that TSH may in turn affect ECV outcome. In 141 women 
(≥ 35 weeks gestation) with a singleton foetus in breech, suitable for ECV, 
demographic, lifestyle and obstetrical parameters were assessed prospectively at 
intake. Blood samples for maternal thyroid parameters (TSH, FT4 and TPO-Ab) 
were taken prior to ECV. ECV success was defined as cephalic presentation 
indicated by post-ECV ultrasound. ECV success rate was overall 77/141 (55%), 





Women with a failed ECV attempt had significantly higher TSH concentrations 
than women with a successful ECV (p< 0.001). Multiple logistic regression 
showed that TSH (OR: 0.52, CI: 0.30-0.90), nulliparity (OR: 0.11, CI: 0.03-0.36), 
frank breech (OR: 0.30, CI: 0.10-0.93), placenta anterior (OR: 0.31, CI: 0.11-
0.85) were all independently related to ECV success. We conclude that women 
with high-normal TSH levels are at increased risk of failed ECV. Future 























Sedert de publicatie van de Term Breech Trial in oktober 2000 is het 
percentage keizersneden bij stuitligging sterk gestegen. De Term Breech Trial 
verwijst naar een grote gerandomiseerde internationale studie die concludeerde 
dat voor een voldragen kind in stuitligging een geplande keizersnede veiliger is 
dan een vaginale baring.  
 
Uitwendige versie is een methode om stuitligging, en dus keizersnede, te 
vermijden. Uit onderzoek blijkt dat uitwendige versie de meest effectieve en 
veilige methode is om het aantal bevallingen in stuitligging te reduceren. 
Internationale richtlijnen bevelen daarom uitwendige versie aan bij deze 
afwijkende foetale ligging. Dit proefschrift betreft een onderzoek naar diverse 
aspecten van stuitligging en uitwendige versie. Bovendien belicht dit proefschrift 
de relatie tussen een suboptimale maternale schildklierfunctie en foetale ligging 
en  de schildklierfunctie van de neonaat.  
 
In hoofdstuk 1, de inleiding, wordt een overzicht gegeven van drie aspecten die 
samenhangen met stuitligging. In de eerste plaats worden in deze context de 
pathofysiologie, epidemiologie, etiologie, spontaan beloop van een stuitligging en 
de gevolgen van een stuitligging voor de moeder en het kind belicht. Vervolgens 
wordt de rol van de maternale schildklierfunctie belicht en worden de gevolgen 
van een suboptimale schildklierfunctie voor de hersenontwikkeling (motoriek, 
gedrag, intellect) van het kind samengevat. Tenslotte wordt een overzicht 
gegeven van de verschillende aspecten van uitwendige versie, zoals de 
geschiedenis, procedure, in- en exclusie criteria, veiligheid, effectiviteit en 
determinanten voor een succesvolle versie. 
 
In hoofdstuk 2 wordt het ontwerp van de thesis verantwoord en toegelicht.  
 
In hoofdstuk 3 wordt het verband tussen suboptimale maternale 
schildklierfunctie en stuitligging op het einde van de zwangerschap onderzocht. 
In de eerste 20 weken van de zwangerschap is een foetus vrijwel volledig 
afhankelijk van de maternale schildklierfunctie. Het is bekend dat suboptimale 
maternale schildklierfunctie een negatieve invloed heeft op de motorische 
ontwikkeling van het kind na de geboorte. Wellicht dat een gebrekkig 
functioneren daarvan de reden is dat een kind in stuit blijft liggen. Om dit te 
onderzoeken werd een groep van 1058 Nederlandse gezonde zwangeren 
prospectief gevolgd vanaf een zwangerschapsduur van 12 weken tot aan de 
bevalling. Maternale schildklierfuncties (TSH, FT4 and TPO-Ab) werden bepaald 
bij een zwangerschapsduur van 12, 24 en 36 weken alsmede de ligging van het 
kind tijdens de geboorte. Tijdens de bevalling lagen 58 kinderen (5.5%) in 
stuitligging. Vergeleken met vrouwen met een kind in hoofdligging, hadden 
vrouwen met een kind in stuitligging significant hogere TSH concentraties bij 





waarden tussen vrouwen met een kind in stuit of met een kind in hoofdligging. 
Het voorkomen van een stuitligging in de subgroep van vrouwen met een TSH ≥ 
2.5 mIU/l (90e percentiel) bij 36 weken zwangerschapsduur was 11%, vergeleken 
met 4.8% in de groep van vrouwen met een TSH < 2.5 mIU/l (p = 0.006). Bij 
vrouwen met een TSH kleiner dan de 5e percentiel was er niemand met een 
stuitligging. Stuitligging was significant en onafhankelijk geassocieerd met 
nullipariteit (OR: 2.71, 95% CI: 1.17 - 5.50), roken (OR: 2.97, 95% CI: 1.23 - 
7.69), geboortegewicht (OR: 0.97, 95% CI: 0.93 - 0.99) en met een hoge-
normale maternale TSH concentratie (≥ 2.5 mIU/l) bij een zwangerschapsduur 
van 36 weken (OR: 2.23, 95% CI: 1.14 - 4.39), maar niet bij een 
zwangerschapsduur van 12 of 24 weken. Conclusie: vrouwen met een TSH 
concentratie van meer dan 2.5 mIU/l, gemeten aan het einde van de 
zwangerschap, lopen meer risico op een stuitligging en in die zin ook een groter 
risico op verloskundige complicaties. 
 
Om de relatie tussen een hoog-normaal maternaal TSH en stuitligging te 
bevestigen in een grotere steekproefomvang, werden in hoofdstuk 4 twee 
studies gecombineerd (hoofdstuk 3 en 9). À terme maternale schildklierfuncties 
(TSH, FT4 and TPO-Ab) in een groep van 189 vrouwen met een kind in 
stuitligging werden vergeleken met een groep van 1000 vrouwen met een kind 
in hoofdligging. Vrouwen met een baby in stuitligging hadden significant hogere 
gemiddelde TSH vergeleken met vrouwen met een kind in hoofdligging. Bij 
opsplitsing van het TSH in verschillende categorieën, bleken er meer vrouwen 
met een kind in stuitligging in de groepen met de hoogste waarden: 90e 
percentiel (TSH > 2.5 mIU/l ), 95e percentiel (TSH > 2.9 mIU/l ) en 97.5e 
percentiel (TSH > 3.4 mIU/l ) vertegenwoordigd. Uit de literatuur blijkt dat een 
aantal artikelen een verband aantoont tussen stuitligging en motorische 
ontwikkelingsachterstand bij het kind. Omdat deze ontwikkelingsachterstand 
ook is geassocieerd met een hoge (hoog-normale) maternale TSH tijdens de 
zwangerschap, zou kunnen worden verondersteld dat suboptimale maternale 
schildklierfunctie in feite het verband verklaart tussen stuitligging en 
ontwikkelingsachterstand.  
 
In hoofdstuk 5 wordt het verband onderzocht tussen de maternale 
schildklierfunctie tijdens ieder trimester van de zwangerschap en het neonatale 
schildklierhormoon verkregen bij de hielprikscreening. Uit de literatuur blijkt 
dat klinisch maternaal schildklierlijden tijdens de zwangerschap is geassocieerd 
met een slechtere neonatale schildklierfunctie. Echter, onderzoek naar het 
verband tussen suboptimale maternale schildklierfunctie (bepaald tijdens ieder 
trimester) en de neonatale schildklierscreening is nauwelijks uitgevoerd. 
Derhalve werd een prospectieve observationele studie bij 886 Nederlandse 
gezonde kaukasische zwangeren en hun pasgeboren kinderen verricht die 





bevalling (≥37 weken). De primaire uitkomstmaat was de relatie tussen de 
neonatale gegevens van de screening op congenitale hypothyroidie en maternale 
schildklierfunctie (TSH, FT4 and TPO-Ab) genomen bij een zwangerschapsduur 
van 12, 24 en 36 weken. Uit de resultaten bleek dat jongens lagere screening 
TT4 waarden hadden; hun moeders hadden hogere TSH waarden bij 24 en 36 
weken zwangerschapsduur. 
Lagere screening TT4 waarden bleken onafhankelijk gerelateerd aan hoog-
normale maternale TSH waarden (> 97.5e percentiel) gedurende een of 
meerdere keren tijdens de zwangerschap (OR: 2.26, 95% CI: 1.20 - 4.29) en een 
kortere zwangerschapsduur bij de bevalling (OR: 0.82, 95% CI: 0.71 - 0.95). 
Concluderend: maternale schildklierfunctie tijdens de zwangerschap is 
gerelateerd aan de neonatale TT4 waarden tijdens hielprikscreening. Een 
opvallende bevinding hierbij was dat vrouwen met een mannelijke foetus hogere 
TSH waarden hadden dan vrouwen met een vrouwelijke foetus. De betekenis 
hiervan is nog niet duidelijk. 
 
In hoofdstuk 6 wordt ingegaan op de vraag welke factoren een rol spelen op 
succesvolle uitwendige versie bij stuitligging. Tevens wordt het effect van een 
poliklinische, geprotocolleerde, uitwendige versie op de wijze van bevallen 
beschreven. 
De studie was opgezet als een retrospectieve analyse van uitwendige versies 
uitgevoerd in het Catharina-ziekenhuis te Eindhoven. In 2003 werd hiervoor een 
standaard protocol ontwikkeld, dat werd getoetst in een ‘versiespreekuur’. 
Volgens dit standaard protocol werd uitwendige versie door 2 obstetrici 
tegelijkertijd verricht, waarbij één van hen deel uitmaakte van een vast team van 
3 ervaren obstetrici. De andere persoon werd gerekruteerd uit de andere 
stafleden van de afdeling obstetrie die geen specifieke ervaring hadden met ECV. 
Weeënremming werd niet routinematig gegeven, maar alleen indien na klinische 
beoordeling van  de uterus vóór versie een verhoogde tonus werd vastgesteld. 
Van alle zwangeren bij wie in de periode januari 2004 - juni 2006 tijdens dit 
spreekuur een poging tot uitwendige versie werd uitgevoerd, werden 
obstetrische kenmerken en de partus geanalyseerd. Van de versies werd 85% 
uitgevoerd door dezelfde 2 personen (1 verloskundige en 1 gynaecoloog), 
volgens het standaardprotocol. Uitwendige versie bleek succesvol bij 96 van de 
209 zwangeren (46%). Bij 1 zwangere moest na de versie een spoedsectio 
worden verricht wegens een partiële abruptio placentae. Nullipariteit, 
onvolkomen stuitligging en een laag geboortegewicht van de baby hingen in deze 
studie samen met een kleinere kans op een succesvolle versie. In de groep 
waarin de versie succesvol was, was het percentage geboorten via keizersnede 
aanmerkelijk lager (9 versus 83%; OR: 0,21; 95%-BI: 0,09-0,51). 
Conclusie is dat uitwendige versie, uitgevoerd volgens een standaardprotocol 
door een vast team, bestaande uit een verloskundige en een gynaecoloog, 





daarmee het percentage keizersneden. Dit leidt tot een aanzienlijke 
gezondheidswinst voor de moeder en een belangrijke kostenbesparing voor de 
gezondheidszorg in Nederland. 
 
In hoofdstuk 7 wordt het effect onderzocht van het verder invoeren van een 
aantal procesmatige beleidsregels - het zogenaamde procesprotocol - op het 
succespercentage van uitwendige versie bij stuitligging. Gedurende een periode 
van 3 jaar (2004-2006) werd dit procesprotocol ontwikkeld, getoetst en 
aangepast. Hierbij werd een aantal procesmatige beleidsregels (procesprotocol 
genoemd) doorgevoerd: de 4 R’s van ‘regelmaat’, ‘routine’, ‘rust’ en ‘relaxatie’. 
• ‘Regelmaat’ hield in: iedere week, op een vast tijdstip, een versiespreekuur. 
• ‘Routine’ betekende dat iedere versie standaard werd uitgevoerd door twee 
obstetrici uit een vast team van 4 personen (2 gynaecologen en 2 
verloskundigen) met specifieke ervaring op ECV gebied. Het team kon dus 
bestaan uit twee verloskundigen, een verloskundige en een gynaecoloog, of twee 
gynaecologen. 
• ‘Rust’ betekende dat de twee ervaren obstetrici tijdens het versiespreekuur 
zoveel mogelijk van andere taken binnen de afdeling obstetrie werden 
vrijgesteld. 
• ‘Relaxatie’ verwees naar het standaard toedienen van een weeënremmer 
tijdens de versiepoging. 
Vervolgens werd na invoering van dit procesprotocol het effect op het 
percentage succesvolle versies prospectief gevolgd gedurende de periode 1 
januari 2007 - 31 juli 2008. Een versie werd als succesvol gedefinieerd als direct 
na de poging echoscopisch een hoofdligging werd aangetoond. Secundaire 
uitkomstmaat was een mogelijke verandering van het aantal primaire sectio’s bij 
stuitligging. 
Na invoering van het procesprotocol (periode januari 2007 - juli 2008) bleek het 
succespercentage van uitwendige versie significant hoger dan in de periode van 
het standaardprotocol (januari 2004 - december 2006) namelijk 61% (85/139 
zwangeren) versus 47% (110/236; p = 0,006). De patiëntkarakteristieken waren 
in beide groepen gelijk, met uitzondering van een klein verschil bij de termijn 
van versie. De stijging was vooral aantoonbaar bij nulliparae en multiparae met 
een onvolkomen stuitligging. Nullipariteit, onvolkomen stuitligging, placenta 
anterior en laag geboortegewicht van de baby waren gerelateerd aan een lagere 
succeskans bij versie. De termijn waarbij de versie plaatsvond bleek niet van 
invloed te zijn op het succespercentage. Na invoering van een procesprotocol 
steeg het aantal hoofdliggingen bij de partus en daalde het aantal primaire 
keizersneden voor stuitligging van 39 naar 27% (p = 0,03). Conclusie: na 
invoering van een procesprotocol vond een aanzienlijke toename plaats van het 
succespercentage van uitwendige versie. Hierdoor daalde het aantal primaire 
sectio’s wegens stuitligging verder. Deze bevindingen pleiten voor het installeren 






Hoofdstuk 8 bevat een commentariële publicatie over de vraag waar de 
uitwendige versie zou moeten plaatsvinden (wel of niet in een ziekenhuis) alsook 
de vraag wie de uitwendige versie zou moeten uitvoeren (de gynaecoloog of de 
verloskundige). In Nederland is er in dit verband een polemiek aangaande het 
beleid van uitwendige versie bij stuitligging. Onder meer in de British Medical 
Journal verscheen hierover een artikel gepubliceerd met de titel “Dutch insurers 
pay midwives not to refer breech presentations to hospital”. In dit artikel wordt 
het contract besproken dat de Koninklijke Nederlandse Organisatie van 
Verloskundigen (KNOV) heeft afgesloten met de Nederlandse 
Zorgverzekeraars om uitwendige versies in de eerste lijn te houden en zo 
minder stuiten naar het ziekenhuis te verwijzen. Naar aanleiding hiervan worden 
in dit hoofdstuk aspecten van veiligheid, succeskans, competentie, training en 
kosteneffectiviteit besproken.  
 
Het eerste aspect heeft betrekking op de vraag waar de versie zou moeten 
plaatsvinden. Uitwendige versie is een relatief veilige procedure, met een overall 
risico op complicaties van 6.1% en waarbij er in 0.4% van de gevallen een 
spoedkeizersnede moet plaatsvinden. Internationale richtlijnen bevelen daarom 
een cardiotocografische bewaking aan met indien nodig de mogelijkheid tot 
spoedkeizersnede. Daarnaast kan door het toedienen van een weeënremmer de 
succeskans verhoogd worden. Het toedienen van een (intraveneuze) 
weeënremmer valt niet onder de bevoegdheid van een Nederlandse eerstelijns 
verloskundige. Daarom dient een uitwendige versie in een ziekenhuis plaats te 
vinden. 
 
Het tweede aspect heeft betrekking op het aspect van de professionele ervaring: 
wie zou de versie moeten uitvoeren, de gynaecoloog of de verloskundige? Een 
uitwendige versie is een relatief eenvoudige ingreep, maar met grote impact op 
de wijze van bevallen van de vrouw. Daarom zou een uitwendige versie alleen 
verricht moeten worden door getrainde professionals met voldoende ervaring. 
Deze professionals kunnen zowel verloskundigen als gynaecologen zijn. 
 
In hoofdstuk 9 wordt een mogelijk verband tussen de maternale 
schildklierfunctie en de succeskans van uitwendige versie onderzocht. Omdat 
vrouwen met een kind in stuitligging significant hogere TSH concentraties bij 
een zwangerschapsduur van 36 weken hebben (zie hoofdstuk 3), kan 
verondersteld worden dat TSH ook een invloed zou kunnen hebben op de 
uitkomst bij uitwendige versie. Bij 141 vrouwen (zwangerschapsduur ≥ 35 
weken) met een eenling in stuitligging waarbij een versie werd verricht, werd 
prospectief een aantal verloskundige en demografische parameters vastgelegd. 
Een uitwendige versie werd als succesvol betiteld indien er direct na de versie 





schildklierfuncties (TSH, FT4 en TPO-Ab) werd afgenomen tijdens de versie. De 
succeskans bij uitwendige versie was voor de gehele groep 77/141 (55%), en 
deze kans was hoger voor multipare 41/48 (85%) dan voor nullipare vrouwen 
36/93 (39%). Vrouwen met een niet gelukte versie hadden significant hogere 
TSH concentraties dan vrouwen met een gelukte versie (p< 0.001). Uit de 
multipele logistische regressie analyse bleek dat TSH (OR: 0.52, CI: 0.30-0.90), 
nullipariteit (OR: 0.11, CI: 0.05-0.36), onvolkomen stuitligging (OR: 0.30, CI: 
0.10-0.93) en anterieure ligging van de placenta (OR: 0.31, CI: 0.11-0.85) 
gerelateerd waren aan de succeskans bij versie. Wij concluderen dat vrouwen 
met een hoog-normale TSH waarde een verhoogd risico hebben op een 
mislukte versie. Toekomstige strategieën op het gebied van ECV zouden daarom 
de rol van maternale TSH-waarden in overweging moeten nemen, om de kans 














ACOG       American College of Obstetricians and Gynecologists 
ADHD       Attention Deficit Hyperactivity Disorder 
AFI          Amniotic Fluid Index 
BI           Betrouwbaarheids Interval 
BMI         Body Mass Index 
CD         Caesarean Delivery 
CH          Congenital Hypothyroidism 
CI          Confidence Interval 
CP          Cerebral Palsy 
CS          Caesarean Section 
CTG        Cardiotocography 
D3          Deiodinase 3 
EBIS         Eindhoven Breech Intervention Study 
ECV         External Cephalic Version 
EFW        Estimated Foetal Weight 
FMH        Foetomaternal Hemorraghe 
FT3         Free Triiodothyronine 
FT4         Free Thyroxine 
HCG        Human Chorionic Gonadotrophin 
HPT-axis:     Hypothalamus-Pituitary-Thyroid axis 
IUGR        Intra Uteriene Groei Retardatie 
KNOV       Koninklijke Nederlandse Organisatie van Verloskundigen 
MN         Mean 
NVOG       Nederlandse Vereniging voor Obstetrie en Gynaecologie 
OR          Odds Ratio 
PPG         Process Policy Guidelines   
PPROM      Preterm Premature Rupture of Membranes 
QALY       Quality Adjusted Life Years 
RANZCOG   Royal Australian and New Zealand College of Obstetricians and  
                     Gynaecologists 
RCT         Randomized Controlled Trial 
RCOG       Royal College of Obstetricians and Gynaecologists 
RR          Relative Risk 
rT3         Reverse T3 
SD          Standard Deviation 
SOGC       Society of Obstetricians and Gynaecologists of Canada  
SPSS         Statistical Package for the Social Sciences 
T3          Triiodothyronine 
T4          Thyroxine 
TBT         Term Breech Trial 
Tg-Ab       Thyroglobulin Antibody 
TPO-Ab      Thyroid Peroxidase Antibody 
TSH         Thyroid Stimulating Hormone or Thyrothrophin 
TSH-R       Thyroid Stimulating Hormone Receptor 
TT4         Total T4 





































Het onderzoek waarvan dit boek getuigt is niet het resultaat van een op 
voorhand geplande actie, integendeel. Om met een metafoor te spreken: er 
hield onverwacht een trein halt en ik meende mee te moeten reizen. Het was 
een spontaan initiatief. Maar goed dat je niet helemaal beseft hoe intensief de 
reis is waar je aan begint... 
 
Prof. dr. V.J.M. Pop. Victor, jij was de machinist. Je was uitnodigend maar wilde 
verder reizen; ik moest snel kiezen of ik wilde opstappen. Je enthousiasme en 
liefde voor het onderzoek en onze gezamenlijke studieachtergrond in Leuven 
maakten voor mij de keuze om de reis te ondernemen gemakkelijker. Onze 
discussies hebben mij enorm geïnspireerd; onvervangbaar. Je coaching, 
ondersteuning en inzicht waren conditiones sine qua non. Een betere promotor 
en collega kan ik me nauwelijks wensen. We moeten nog een paar haltes en ik 
verheug mij op de verdere rit. Op ‘Station Riethoven’ wil ik nog vaak halt 
houden, ook voor de geweldige koffie van Bernadette. 
 
Dr. T.H.M. Hasaart. Beste Tom, je komst naar Eindhoven heeft mij de ruimte 
gegeven me wetenschappelijk en als arts verder te kunnen ontplooien. Je 
kritische opmerkingen hebben het onderzoek verbeterd en diepgang gebracht. 
Feilloos wist je iedere keer de vinger op de wonde te leggen. Samenwerken met 
jou is echt constructief en verrijkend. Als levensgenieters pur sang hebben jij en 
Claire, Maurice en mij bovendien aangestoken op andere domeinen dan de 
medische. Graag laten wij ons verder door jullie inspireren! 
 
Prof. dr. L. Kooistra. Beste Libbe, hoe had dit gemoeten zonder je kritische 
vragen en zonder je kritiek op onze cirkelredeneringen? Een mens kan veel 
talenten hebben, dat heb ik bij jou gezien. Hoe anders carrières als 
profvoetballer, molenaar en wetenschapper te combineren? 
 
Prof. dr. S.G. Oei. Beste Guid, dank je voor je participatie aan deze studie. 
Ondanks je drukke agenda is het je toch gelukt met ons mee te denken en 
schrijven. 
 
Prof. dr. H.L. Vader. Beste Huib, dank voor al je analyses, het meedenken en 
brainstormen. Ik hoop dat wij nog vaak samen mogen studeren op nieuwe 
analyses. Er is nog zoveel dat we nog niet begrijpen. 
 
Dr. T. Vulsma. Beste Tom, dank voor je waardevolle inzichten. De 
wisselwerking maternale/foetale schildklierfunctie is nog een echte “black box”. 
De gedrevenheid van mensen zoals jij zijn noodzakelijk om wat licht in de 





Dr. H.A. Wijnen. Beste Hennie, hartelijk dank dat ik mocht putten uit de 
gigantische database die je hebt aangelegd ten behoeve van je eigen onderzoek. 
Onze hypotheses over stuitligging konden we aan de hand daarvan testen. 
 
Dr. C. Bruynen. Beste Chris, als wijze dokter en raadgever op cruciale 
momenten in mijn carrière wil ik je van harte danken. Ik hoop nog lang van je 
adviezen te mogen genieten. 
 
Dr. E. Nolting. Beste Ernst, door jouw schat aan kennis, ervaring en talent, ben 
je steeds in staat goede adviezen te geven. Hartelijk dank hiervoor. 
 
M.W.P van der Donk. Lieve Riet, het hele “versie gebeuren” is mede mogelijk 
geweest door jouw organisatietalent, enthousiasme en creatieve ideeën. Telkens 
kwam je met nuchtere inzichten en mogelijke verklaringen. Ik hoop dat ik nog 
heel lang met jou verder mag “draaien”: “Yes, we can!” 
 
I. de Leeuw. Lieve Ingrid, een knappe stuit die onder jouw handen door kan 
glippen. Ik ben blij dat jij ons versieteam compleet maakt. Ik hoop dat ook wij 
nog lang mogen samenwerken. 
 
C. Weber-Swinkels. Lieve Caterine, zonder de nauwkeurige registratie van ons 
doen en laten hadden wij deze studie nooit kunnen doen. Bovendien ben je in 
staat patiënten op hun gemak te stellen. Onmisbaar. 
 
F. Lemmens. Beste Fieke, dank voor het maken van het code-boek en opzetten 
van de SPSS-bestanden. 
 
A. van der Stokke. Beste Anton, hartelijk dank voor het bewaken van de voor 
mij zo kostbare buisjes bloed en urine. 
 
Jolanda en Ellen, beste bibliothecaressen, hartelijk dank voor jullie hulp bij het 
opmaken van de referenties. 
 
Beste Marieke, Mayke, Ben, Anne en Evelyne. Dank voor de enthousiaste 
medewerking aan een van de artikelen. Jullie zijn prima arts-assistenten en ik 
wens jullie heel veel succes met jullie verdere carrière. 
 
Beste maten, door de jaren heen hebben we telkens samen moeten vechten. Nu 
we de grootste hindernissen overwonnen hebben ligt een nog betere toekomst 





Verloskamerverpleegkundigen en tweedelijns verloskundigen. Dank voor jullie 
inzet. Gegevens verzamelen in een hectische omgeving: zonder jullie hulp was 
dat niet mogelijk geweest. Jullie zijn een fantastisch team. 
 
Beste arts-assistenten. Jullie komen en gaan, en iedere keer valt het mij op 
hoezeer we aan elkaar gehecht raken. Het vertrek van een van jullie blijkt altijd 
spijtig. Dank voor jullie hulp bij deze studie. 
 
Beste eerstelijns verloskundigen. Zonder jullie vertrouwen en het verwijzen van 
patiënten naar ons team was deze studie niet mogelijk geweest. Dank ook voor 
het verzamelen van navelstrengbloed en het meten van navelstrenglengtes en 
windingen. 
 
Alle patiënten die deelgenomen hebben aan de studie wil ik van harte bedanken 
voor het belangeloos invullen van de vragenlijsten. 
 
Secretariaat Gynaecologie, Sandra en Sabrina. Wat een ondersteuning, al dat 
correctiewerk en geregel. Geweldig. 
 
Beste Toon Kees, hartelijk dank voor je eindeloze geduld en vele uren werk, 
met het animatiefilmpje en de cover van dit proefschrift tot resultaat. Ik er heel 
blij mee. 
 
Liewe Leanie, baie dankie vir die tekeninge van die eksterne hoof draaiing 
tegniek.   
Dit is ongelooflik hoe 'n kunstenaar soos jy dinge raak sien, wat ons nie eers 
bewus van was nie. Jou tekeninge en presisie het ons genoop om mooi na te 
dink oor ons draai-tegniek en dit in stappe te analiseer. Dit was van onskaatlike 
waarde vir my! 
 
Lieve familie, Nederlandse, Vlaamse, Afrikaanse en andere vrienden en 
bekenden. Door alle drukte is het niet mogelijk geweest om elkaar regelmatig te 
blijven ontmoeten. Maar als we toch bij elkaar zijn valt het op dat alles binnen 
een paar minuten weer zoals vroeger is. We hebben veel mooie herinneringen 
en zullen nog veel mooie momenten met elkaar beleven. 
 
Speciale dank aan mijn buurman en goede vriend Jan van Gemert voor de hulp 
bij het opmaken van grafieken en tabellen. 
 
Lieve Stefanie en Jeanine, dank dat jullie paranimf willen zijn. Jullie enthousiasme 





Joris, lieve broer. Ik ken niemand die zich zo kan uitleven met zijn neefje en 
nichtjes. Dank voor al je tijd. Het gaf mij de gelegenheid om door te werken aan 
deze studie. 
 
Speciale dank aan mijn ouders en schoonmoeder voor de onvoorwaardelijke 
steun aan ons gezin. Papa, jouw woorden “gewoen doorgoan” als het soms wat 
minder ging zijn een stevige ondersteuning gebleken. Mama, in de moeilijke 
momenten ben jij degene die mij het beste begrijpt en helpt. Vaak door alleen 
maar te luisteren. Omi, het gezins- en familieleven staan bij jou altijd op de 
eerste plaats. Daar kunnen we iets van leren. Dank voor de 
maandagavondetentjes. 
 
Lieve Thomas en Sophie, eindelijk is het “boekje” af, en krijgen wij meer tijd om 
samen door te brengen. Ik ben ontzettend trots op jullie. De woensdagmiddag 
wordt weer van ons! 
 
Lieve Maurice, tot slot, het was een leuke periode die op het einde heftiger 
werd. Het is goed dat het nu afgerond wordt. Samen hebben wij deze weg 
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Stellingen behorende bij het proefschrift: 
 
Successful External Cephalic Version in Breech 
Thyroid hormone and process parameters 
 
 
1.  Een uitwendige versie bij stuitligging is een must: “Nee” heb je; “Ja” kun je 
krijgen. 
2.  Zwangeren met een TSH concentratie boven 2.5 mIU/l in het derde 
trimester hebben 2 keer meer risico op een stuitligging en bijgevolg op 
verloskundige complicaties. (dit proefschrift) 
3.  De in de literatuur beschreven samenhang tussen stuitligging en 
ontwikkelingsstoornissen bij het kind is mogelijk schildklierhormoon 
gemedieerd. 
4.  Het succespercentage van versie neemt aanzienlijk toe door het invoeren van 
een aantal beleidsregels (4R’s: ‘regelmaat’, ‘routine’, ‘rust’ en ‘relaxatie’).  
 (dit proefschrift) 
5.  De bevindingen uit dit proefschrift vormen een pleidooi voor het oprichten 
van 2e lijnscentra, gespecialiseerd in uitwendige versie. 
6.  Zwangeren met een TSH concentratie boven 2.5 mIU/l in het derde 
trimester hebben 2.5 keer meer risico op een mislukte versie.            
 (dit proefschrift) 
7.  Een foetus in hoofdligging heeft zijn eerste citotoets  succesvol afgelegd. 
8.  Daars geen wyer draai as ‘n afrikaanse draai: dis die beste plek om jou hart af 
te laai.  (vrij naar Steve Hofmeyr) 
9.  It is better to light a lamp, than to curse the darkness.                 
(Father Jos Kuppens, Centre for Social Concern, Malawi). 
 
Simone Kuppens, augustus 2010 

